Nabriva Therapeutics (NBRVF) 10-K 11 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Feb. 28, 2021	Jun. 30, 2020
Document And Entity Information
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2020
Entity File Number	001-37558
Entity Registrant Name	Nabriva Therapeutics plc
Entity Incorporation, State or Country Code	L2
Entity Address, Address Line One	25-28 North Wall Quay
Entity Address, Address Line Two	IFSC
Entity Address, City or Town	Dublin 1
Entity Address, Country	IE
Entity Tax Identification Number	00-0000000
Entity Address, Postal Zip Code	00000
City Area Code	353 1
Local Phone Number	649 2000
Title of 12(b) Security	Ordinary Shares, nominal value $0.01 per share
Trading Symbol	NBRV
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Shares Outstanding		25,024,653
Entity Central Index Key	0001641640
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Public Float			$ 95.2
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
ICFR Auditor Attestation Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 41,359	$ 86,019
Restricted cash	231	392
Short-term investments	16	175
Accounts receivable, net and other receivables	3,909	2,744
Inventory	5,823	682
Prepaid expenses	5,880	1,158
Total current assets	57,218	91,170
Property, plant and equipment, net	768	2,474
Intangible assets, net	80	91
Long-term receivables	370	378
Total assets	58,436	94,113
Current liabilities:
Current portion of long-term debt	2,041
Accounts payable	2,889	4,673
Accrued expense and other current liabilities	12,844	11,966
Deferred revenue	750
Total current liabilities	18,524	16,639
Non-current liabilities
Long-term debt	5,686	34,502
Other non-current liabilities	1,091	1,698
Total non-current liabilities	6,777	36,200
Total liabilities	25,301	52,839
Commitments and contingencies (Note 17)
Stockholders' Equity:
Ordinary shares, nominal value $0.01, 100,000,000 ordinary shares authorized at December 31, 2020; 9,454,511 and 21,078,781 issued and outstanding at December 31, 2019 and December 31, 2020, respectively	211	95
Preferred shares, par value $0.01, 10,000,000 shares authorized at December 31, 2020; None issued and outstanding
Additional paid in capital	579,123	517,894
Accumulated other comprehensive income	27	27
Accumulated deficit	(546,226)	(476,742)
Total stockholders' equity	33,135	41,274
Total liabilities and stockholders' equity	$ 58,436	$ 94,113

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Consolidated Balance Sheets
Ordinary stock, nominal value (in dollars per share)	$ 0.01	$ 0.01
Ordinary stock, authorized shares	100,000,000	100,000,000
Ordinary stock, issued shares	21,078,781	9,454,511
Ordinary stock, outstanding shares	21,078,781	9,454,511
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized shares	100,000,000	100,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues:
Total revenue	$ 5,027	$ 9,481	$ 9,656
Operating expenses:
Cost of product sales	(766)	(70)
Research and development expenses	(15,102)	(26,415)	(82,288)
Selling, general and administrative expenses	(55,285)	(62,485)	(41,743)
Total operating expenses	(71,153)	(88,970)	(124,031)
Loss from operations	(66,126)	(79,489)	(114,375)
Other income (expense):
Other income (expense), net	1,187	215	(272)
Interest income	86	255	49
Interest expense	(1,735)	(3,644)	(133)
Loss on extinguishment of debt	(2,757)
Loss before income taxes	(69,345)	(82,663)	(114,731)
Income tax expense	(139)	(101)	(49)
Net loss	$ (69,484)	$ (82,764)	$ (114,780)
Loss per share
Basic and Diluted ($ per share)	$ (5.41)	$ (11.15)	$ (22.60)
Weighted average number of shares:
Basic and Diluted	12,845,089	7,419,948	5,079,576
Product revenue, net
Revenues:
Total revenue	$ 108	$ 1,538
Collaboration revenue
Revenues:
Total revenue	2,756	6,210	$ 6,500
Research premium and grant revenue
Revenues:
Total revenue	$ 2,163	$ 1,733	$ 3,156

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock/Ordinary Shares	Additional paid in capital	Accumulated other comprehensive income	Accumulated deficit	Total
Stockholders' equity, beginning balance at Dec. 31, 2017	$ 37	$ 361,202	$ 27	$ (279,198)	$ 82,068
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2017	3,671
Consolidated Statements of Changes in Stockholders' Equity
Issuance of ordinary shares	$ 23	74,196			74,219
Issuance of ordinary shares (in shares)	2,297
Shares issued in connection with the acquisition of Zavante Therapeutics, Inc.	$ 7	26,895			26,902
Shares issued in connection with the acquisition of Zavante Therapeutics, Inc. (in shares)	734
Equity transaction costs		(4,933)			(4,933)
Stock-based compensation expense		5,154			5,154
Net loss				(114,780)	(114,780)
Stockholders' equity, ending balance at Dec. 31, 2018	$ 67	462,514	27	(393,978)	68,630
Stockholders' equity, ending balance (in shares) at Dec. 31, 2018	6,702
Consolidated Statements of Changes in Stockholders' Equity
Issuance of ordinary shares and warrants	$ 26	48,056			48,082
Issuance of ordinary shares and warrants (in shares)	2,584
Shares issued in connection with the vesting of restricted stock units	$ 1	(1)
Shares issued in connection with the vesting of restricted stock units (in shares)	66
Shares issued in connection with the employee stock purchase plan		372			372
Shares issued in connection with the employee stock purchase plan (in shares)	21
Shares issued in connection with the acquisition of Zavante Therapeutics, Inc.	$ 1	(1)
Shares issued in connection with the acquisition of Zavante Therapeutics, Inc. (in shares)	82
Equity transaction costs		(2,794)			(2,794)
Stock-based compensation expense		9,748			9,748
Net loss				(82,764)	(82,764)
Stockholders' equity, ending balance at Dec. 31, 2019	$ 95	517,894	27	(476,742)	41,274
Stockholders' equity, ending balance (in shares) at Dec. 31, 2019	9,455
Consolidated Statements of Changes in Stockholders' Equity
Issuance of ordinary shares	$ 116	60,944			61,060
Issuance of ordinary shares (in shares)	11,571
Shares issued in connection with the vesting of restricted stock units (in shares)	44
Shares issued in connection with the employee stock purchase plan		43			43
Shares issued in connection with the employee stock purchase plan (in shares)	9
Equity transaction costs		(4,977)			(4,977)
Stock-based compensation expense		5,219			5,219
Net loss				(69,484)	(69,484)
Stockholders' equity, ending balance at Dec. 31, 2020	$ 211	$ 579,123	$ 27	$ (546,226)	$ 33,135
Stockholders' equity, ending balance (in shares) at Dec. 31, 2020	21,079

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net loss	$ (69,484)	$ (82,764)	$ (114,780)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash other income/expense, net	50	(40)	362
Non-cash interest income		22	45
Non-cash interest expense	636	519	(104)
Loss on extinguishment of debt	2,757
Depreciation and amortization expense	417	396	510
Amortization of right-of-use assets	403	374
Stock-based compensation	5,219	9,748	5,154
In-process research and development in connection with acquisition			32,048
Other, net	62	48	14
Changes in operating assets and liabilities:
Increase/(decrease) in long-term receivables	8	50	(3)
Increase/(decrease) in accounts receivable, net and other receivables and prepaid expenses	(5,887)	2,582	1,139
Increase in inventory	(5,141)	(682)
Increase/(decrease) in accounts payable	(1,813)	1,310	(2,969)
Increase/(decrease) in accrued expenses and other liabilities	714	(3,209)	5,742
Increase in deferred revenue	750
Increase/(decrease) in other non-current liabilities	(2)	(172)	61
Increase/(decrease) in income tax liabilities	(20)	(74)	58
Net cash used in operating activities	(71,331)	(71,892)	(72,723)
Cash flows from investing activities
Purchases of plant and equipment and intangible assets	(113)	(61)	(229)
Purchases of term deposits			(115)
Changes in restricted cash	(161)	392
Transaction costs related to Zavante acquisition, net of cash acquired			(4,260)
Net cash used in investing activities	(274)	331	(4,604)
Cash flows from financing activities
Proceeds from exercise of warrants	665
Proceeds from issuance of ordinary shares and warrants	53,460	20,138	50,000
Proceeds from at-the-market facility	7,520	27,945	24,219
Proceeds from long-term debt, net of issuance costs		9,980	23,545
Proceeds from employee stock purchase plan	43	372
Repayments of long-term borrowings	(30,000)
Equity transaction costs	(4,764)	(2,360)	(4,841)
Net cash provided by financing activities	26,924	56,075	92,923
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	(140)	(106)	(362)
Net increase/(decrease) in cash, cash equivalents and restricted cash	(44,821)	(15,592)	15,234
Cash, cash equivalents, and restricted cash at beginning of year	86,411	102,003	86,769
Cash, cash equivalents and restricted cash at end of year	41,590	86,411	102,003
Supplemental disclosure of cash flow information:
Interest paid	1,396	2,560	7
Taxes paid	(4)	(11)	(4)
Equity transaction costs incurred in prior periods and paid in current period	$ 765	$ 552	$ 120

Organization and Business Activ

Organization and Business Activities	12 Months Ended
	Dec. 31, 2020
Organization and Business Activities
Organization and Business Activities	1. Organization and Business Activities Nabriva Therapeutics plc, or Nabriva Ireland, together with its wholly owned and consolidated subsidiaries, Nabriva Therapeutics GmbH, or Nabriva Austria, Nabriva Therapeutics US, Inc., and Nabriva Therapeutics Ireland DAC, collectively, Nabriva, or the Company, is a biopharmaceutical company engaged in the commercialization and development of novel anti-infective agents to treat serious infections. The Company’s headquarters are located at 25-28 North Wall Quay, Dublin, Ireland. In September 2020, the Centers for Medicare & Medicaid Services, or CMS, granted a new technology add-on payment, or NTAP, for XENLETA® (lefamulin) for injection, when administered in the hospital inpatient setting. Both the intravenous, or IV and oral formulations of XENLETA were granted Qualified Infectious Disease Product, or QIDP, and Fast Track designation by the U.S. Food and Drug Administration, or FDA. CONTEPO was granted an NTAP making it the first QIDP antibiotic to be granted conditional NTAP approval prior to receiving FDA approval. CONTEPO was granted QIDP and Fast Track Designation by the FDA for the treatment of complicated urinary tract infections, or cUTIs, including acute pyelonephritis. In July 2020, the Company announced that the European Commission, or EC, issued a legally binding decision for approval of the marketing authorization application for XENLETA™ (lefamulin) for the treatment of community-acquired pneumonia, or CAP, in adults following a review by the European Medicines Agency, or EMA. The EMA approval of XENLETA in CAP patients when it is considered inappropriate to use antibacterial agents that are commonly recommended for initial treatment or when these agents have failed paves the way for the launch of XENLETA across the European Economic Area, or EEA, and United Kingdom, or U.K. The EC approved XENLETA for all countries of the European Economic Area, or EEA, and United Kingdom, or U.K. Nabriva intends to work with a commercial partner to make XENLETA available to patients in the European Economic Area, or EEA, and United Kingdom, or U.K. In July 2020, the Company announced that Sunovion Pharmaceuticals Canada Inc., or Sunovion, received approval from Health Canada to market oral and IV formulations of XENLETA® (lefamulin) for the treatment of CAP in adults, with the Notice of Compliance from Health Canada dated July 10, 2020. Nabriva entered into a license and commercialization agreement in March 2019 with Sunovion Pharmaceuticals Canada Inc. for XENLETA in Canada. In July 2020, the Company announced that it entered into a Sales Promotion and Distribution Agreement, or the Distribution Agreement, with MSD International GmbH, or MSD, and Merck Sharp & Dohme Corp., or Supplier, each a subsidiary of Merck & Co. Under the Distribution Agreement, MSD appointed the Company as its sole and exclusive distributor of certain products containing tedizolid phosphate as the active ingredient previously marketed and sold by Supplier and MSD under the trademark SIVEXTRO® for injection, intravenous use and oral use in the United States and its territories. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible Gram-positive microorganisms. Nabriva has also engaged Amplity Health, a leading pharmaceutical contract commercial organization, to provide community-based commercial and sales services for SIVEXTRO and XENLETA® in the United States. In June 2020 the Company announced that WE Pharma Ltd., or WEP Clinical, a specialist pharmaceutical services company, had signed an exclusive agreement with the Company to supply XENLETA® (lefamulin) on a named patient or expanded access basis in certain countries outside of the US, China and Canada. The Named Patient Program, or NPP, is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet available and have an unmet medical need. In September 2019, the Company announced that the oral and IV formulations of XENLETA (lefamulin) are available in the United States for the treatment of community-acquired bacterial pneumonia, or CABP, through major specialty distributors. This followed the approval by the FDA of the Company’s New Drug Application, or NDA, for XENLETA on August 19, 2019 for the treatment of adults with CABP. XENLETA is the first oral and IV treatment in the pleuromutilin class of antibiotics available for the systematic administration in humans. In July 2018, the Company acquired Zavante Therapeutics Inc., or Zavante, a biopharmaceutical company focused on developing CONTEPO (fosfomycin for injection), and entered into an Agreement and Plan of Merger, or the Merger Agreement. CONTEPO is potentially a first-in-class epoxide antibiotic for IV administration in the United States. The Company is developing CONTEPO IV for cUTI and may potentially develop XENLETA and CONTEPO for additional indications. In April 2019, the FDA issued a Complete Response Letter, or CRL, in connection with the Company’s NDA for CONTEPO for the treatment of cUTIs, including acute pyelonephritis, stating that it was unable to approve the application in its current form. The CRL requests that issues related to facility inspections and manufacturing deficiencies at Nabriva’s active pharmaceutical ingredient contract manufacturer be addressed prior to the FDA approving the NDA. The Company requested a “Type A” meeting with the FDA to discuss its findings and this meeting occurred in July 2019. As the FDA did not request any new clinical data and did not raise any other concerns with regard to the safety or efficacy of CONTEPO in the CRL, the purpose of the meeting was to discuss and gain clarity on the issues related to facility inspections and manufacturing deficiencies at one of Nabriva's contract manufacturers that were described in the CRL and other matters pertaining to the steps required for the resubmission of the NDA for CONTEPO. The Company resubmitted its NDA in December 2019 and the FDA acknowledged the resubmission in January 2020. In June 2020, the FDA issued a second CRL on the NDA for CONTEPO. Although the Company’s European contract manufacturing partners were prepared for regulatory authority inspections, the CRL cites observations at the Company’s manufacturing partners that could not be resolved due to FDA’s inability to conduct onsite inspections because of travel restrictions caused by the COVID-19 pandemic. In general, previously identified product quality and facility inspection related observations at the Company’s contract manufacturing partners are required to be satisfactorily resolved before the NDA may be approved. The FDA did not request any new clinical data and did not raise any other concerns with regard to the safety or efficacy of CONTEPO in the second CRL. The Company’s contract manufacturers continue to interact with FDA to discuss its plans for conducting inspections at their sites. On October 30, 2020, the Company participated in a Type A meeting with the FDA to obtain any new information related to the FDA’s pending conduct of inspections of foreign manufacturers during the COVID-19 pandemic that has negatively impacted a number of FDA product reviews, including the CONTEPO NDA. The FDA informed the Company that it has not yet determined how it will conduct international inspections during the COVID-19 pandemic. As a result, next steps and specific timing of the CONTEPO NDA resubmission cannot be finalized until the FDA issues industry guidance. The Company and the industry await future communication from the FDA as it continues to assess the options available under existing regulations and laws to conduct these foreign facility inspections. CONTEPO has been granted Qualified Infectious Disease Product, or QIDP, and Fast Track designations by the FDA for the treatment of serious infections, including cUTI. However, the Company cannot predict when the CONTEPO NDA will be resubmitted or when CONTEPO would receive marketing approval, if at all. Liquidity Since its inception, the Company has incurred net losses and generated negative cash flows from its operations which has resulted in a significant accumulated deficit to date. The Company has financed its operations through the sale of equity securities, convertible and term debt financings and research and development support from governmental grants and proceeds from its licensing agreements. As of December 31, 2020, the Company had cash and cash equivalents, restricted cash and short-term investments of $41.6 million. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40 , Presentation of Financial Statements Going Concern The Company expects to continue to invest in critical commercial and medical affairs activities, its commitments per the agreement with Merck & Co., Inc., as well as investing in its supply chain for the commercialization of XENLETA, SIVEXTRO and the potential launch of CONTEPO. The Company expects to seek additional funding in future periods to support these activities. While the Company has raised capital in the past, the ability to raise capital in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future capital raises in their assessment of the Company’s ability to meet its obligations for the next twelve months. ​ In April 2020, the Company announced a restructuring of its hospital-based commercial sales force and transition to a community-based sales effort. The restructuring has reduced costs to align with the capabilities of the Company’s sales effort with its strategic re-focus on making sales of XENLETA to community health care professionals. The termination of the sales force was timed, in part, to coincide with operational changes that have been implemented by the Company in response to the outbreak of the novel coronavirus, SARS-CoV-2, causing the disease referred to as “COVID-19”. In response to the COVID-19 pandemic, the Company closed its administrative offices and shifted to a remote working business model. The Company implemented a work-from-home policy for all of its employees. The commercial and medical organizations suspended in-person interactions with physicians and customers and were restricted to conducting educational and promotional activities virtually. The Company has secured a new virtual and in-person sales effort with community-based expertise with Amplity Health, which is a Contract Sales Organization, to replace its hospital-based sale force. In September 2020, the Company began a small and focused sales effort for SIVEXTRO and XENLETA, by utilizing 15 sales representatives. The Company expanded this effort to 60 sales representatives in November 2020 and the Company may expand it further in 2021. ​ The Company’s expenses will increase if it suffers any regulatory delays or is required to conduct additional clinical trials to satisfy regulatory requirements. The Company has incurred and expects to continue to incur significant commercialization expenses related to its commitments per the agreement with Merck & Co., Inc., product sales, marketing, distribution and manufacturing for XENLETA, SIVEXTRO and CONTEPO, if approved. It is also uncertain when, if ever, the Company will generate sufficient revenues from product sales to achieve profitability. As a result, based on the Company’s available cash resources, the minimum cash required under the Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc., and in accordance with the requirements of ASC 205-40, management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. A failure to raise the additional funding or to effectively implement cost reductions could harm the Company’s business, results of operations and future prospects. If the Company is not able to secure adequate additional funding in future periods, the Company may make additional reductions in certain expenditures. This may include liquidating assets and suspending or curtailing planned programs. The Company may also have to delay, reduce the scope of, suspend or eliminate one or more research and development programs or its commercialization efforts. Based on its current operating plans, the Company expects that its existing cash, cash equivalents, restricted cash and short-term investments as of the date of this filing will be sufficient to enable the Company to fund its operating expenses, debt service obligations and capital expenditure requirements into the fourth quarter of 2021. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its capital resources sooner than expected. This estimate assumes, among other things, that the Company does not obtain any additional funding through grants and clinical trial support, collaboration agreements or equity or debt financings. This estimate also assumes that the Company remains in compliance with the covenants and no event of default occurs under the Loan Agreement. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. In June 2019, the Company entered into an Open Market Sale Agreement SM Offering under the Company’s new shelf Registration Statement on Form S-3 (File No. 333-248530), which became effective on September 11, 2020. As of December 31, 2020, the Company has issued and sold an aggregate of 1,992,390 ordinary shares pursuant to the Jefferies ATM Agreement and received gross proceeds of $21.9 million and net proceeds of $20.4 million, after deducting commissions to Jefferies and other offering expenses. From January 1, 2021 and through the date of this filing, the Company sold and issued 3,933,350 ordinary shares pursuant to the Jefferies ATM Agreement for net proceeds of approximately $11.5 million. As of the date of this filing, the Company may issue and sell ordinary shares for gross proceeds of up to $16.3 million under the Jefferies ATM Agreement. In May 2020, the Company sold to certain institutional investors, including Fidelity Management & Research Company, LLC, in a registered direct offering an aggregate of 4,144,537 ordinary shares and accompanying warrants to purchase up to an aggregate of 4,144,537 ordinary shares at a combined price of $9.1686 per security. The proceeds to the Company from the offering were $38.0 million gross and $35.2 million net, after deducting the placement agent’s fees and other offering expenses. As of December 31, 2020, there were 4,059,532 warrants outstanding, where each warrant has an exercise price of $7.92 per share and is immediately exercisable and will expire on the two-year In December 2020, the Company completed a registered public offering in which it sold 6,000,000 ordinary shares at a public offering price of $2.50. The proceeds to the Company from the offering were $15.0 million gross and $13.3 million net, after deducting the placement agent’s fees and other offering expenses. In March 2021, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to issue and sell in a registered direct offering (1) an aggregate of 9,761,010 ordinary shares, $0.01 nominal value per share, and accompanying warrants to purchase up to an aggregate of 4,880,505 ordinary shares and (2) pre-funded warrants to purchase up to an aggregate of 600,000 ordinary shares and accompanying ordinary share warrants to purchase up to an aggregate of 300,000 ordinary shares. Each share was issued and sold together with an accompanying ordinary share warrant at a combined price of $2.4525, and each pre-funded warrant was issued and sold together with an accompanying ordinary share warrant at a combined price of $2.4425. The proceeds to us from the offering were $25.4 million gross and $23.4 million net after deducting the placement agent’s fees and other estimated offering expenses. Each pre-funded warrant had an exercise price per ordinary share equal to $0.01 and each pre-funded warrant was exercised in full on the issuance date. Each ordinary share warrant has an exercise price per ordinary share equal to $2.39, was exercisable on the date of issuance and will expire on the five-year anniversary of the date of issuance.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Preparation The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or US GAAP, and US Securities and Exchange Commission, or SEC, regulations for annual reporting. The consolidated financial statements include the accounts of Nabriva Therapeutics plc and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Reverse Stock Split On December 2, 2020, the Company filed an Amended and Restated Memorandum and Articles of Association of the Company with the Irish Companies Registration Office and effected, a one-for-ten reverse stock split (the “Reverse Stock Split”) of the Company’s ordinary shares. As a result of the Reverse Stock Split, every ten ordinary shares in the authorized and unissued and authorized and issued share capital of the Company were consolidated into one ordinary share. No fractional shares were issued in connection with the Reverse Stock Split. Shareholders who would otherwise be entitled to a fractional ordinary share were instead entitled to receive a proportional cash payment. All ordinary share, per share and related information presented in the consolidated financial statements and notes has been retroactively adjusted to reflect the Reverse Stock Split. Functional Currency Transactions and Balances In preparing the consolidated financial statements, transactions in currencies other than the U.S. dollar are recognized at the exchange rates prevailing at the dates of the transactions. Foreign currency exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statements of operations. Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. Restricted Cash ​ The Company classifies funds contributed by its employees to its Employee Stock Purchase Plan (See Note 11) as restricted in nature since these amounts can only be utilized to purchase Company stock at the end of each six month offering period. Prior to the conclusion of the offering period, employees can request reimbursement of the funds they previously contributed and if they leave the Company prior to the end of the offering period the funds are returned to the employee. ​ Short-term Investments The Company has designated its investments in securities as available-for-sale securities and measures these securities at their respective fair values. Investments that mature in one year or less are classified as short-term available-for-sale securities. Investments that are not considered available for use in current operations are classified as long-term available-for-sale securities. Changes in the fair value of available-for-sale investments are recognized in other comprehensive income (loss). Inventory ​ Inventory is stated at the lower of cost or net realizable value. Inventory is valued on a first-in, first-out basis and consists primarily of material costs, third-party manufacturing costs, and related transportation costs along the Company's supply chain. The Company capitalizes inventory upon regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are recorded as research and development expense. Costs of drug product to be consumed in any current or future clinical trials will continue to be recognized as research and development expense and costs of sample inventory is recorded as selling, general and administrative expense. The Company reviews inventories for realization on a quarterly basis and would record provisions for estimated excess, slow-moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value when necessary. For the year ended December 31, 2020, the Company recorded a $0.7 million non-cash reserve for excess and obsolete inventory due to the uncertainty of commercial activities underlying XENLETA product sales. ​ The components of our inventory at December 31, 2019 and 2020 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands) ​ 2019 ​ ​ 2020 Raw materials $ — ​ $ 952 Work in process 498 ​ 4,608 Finished goods 184 ​ 263 Total Inventory $ 682 ​ $ 5,823 ​ ​ Property, Plant and Equipment Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are as follows: 3 5 3 Intangible Assets and Other Long-lived Assets Intangible assets, such as acquired computer software licenses, are capitalized on the basis of the costs incurred to acquire the software and bring it into use. These costs are amortized on a straight-line basis over their estimated useful lives ( 3 Long-lived assets are assessed for potential impairment when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. An impairment loss would be recognized when undiscounted cash flows expected to be generated by an asset, is less than its carrying amount. The impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value and recognized in these financial statements. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating segment, which is the commercialization and development of novel anti-infective agents to treat serious and life-threatening infections. Revenue Recognition Revenue from Contracts with Customers Net Product Revenue Beginning in September 2019, the Company began selling its XENLETA product principally to a limited number of specialty distributors in the United States. The distributors place orders with the Company for sufficient quantities of its products to maintain an appropriate level of inventory based on its customers’ anticipated purchase volumes and demand. The Company recognizes revenue once it has transferred physical possession of the goods and the distributor obtains legal title to the product. Payment terms between Nabriva and its customers are generally approximately 60 days from the invoice date. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of its product. The transaction price that the Company recognizes as revenue reflects the amount it expects to be entitled to in connection with the sale and transfer of control of product to its customers. At the time that the Company’s customers take control of the product, which is when the Company’s performance obligation under the sales contracts is complete, the Company records product revenues net of applicable reserves for various types of variable consideration. The types of variable consideration are as follows: ● Fees-for-service ● Product returns ● Chargebacks and rebates ● Government rebates ● Commercial payer and other rebates ● Group Purchasing Organizations, or GPO, administration fees ● Voluntary patient assistance programs In determining the amounts of certain allowances and accruals, the Company must make significant judgments and estimates. For example, in determining these amounts, the Company estimates prescription demand from the specialty pharmacies, hospital demand, buying patterns by hospitals, hospital systems and/or group purchasing organizations and the levels of inventory held by specialty distributors and customers. The Company also analyzes third party end usage product consumption patterns to gauge demand for its products. Making these determinations involves analyzing third party industry data to determine whether trends in historical channel distribution patterns will predict future product sales. The Company receives data periodically from its specialty distributors and customers on inventory levels and historical channel sales mix, and the Company considers this data when determining the amount of the allowances and accruals for variable consideration, however given the recent launch of its XENLETA product this data is limited. In assessing the amount of net revenue to record, the Company considers both the likelihood and the magnitude of the revenue reversal. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. The specific considerations the Company uses in estimating these amounts related to variable consideration associated with the Company’s products are as follows: Fees-for-service does not consider the fees separate from the distributors’ purchase of the product. The Company records its fee-for-service accruals based on distributors’ purchases and the applicable discount rate. Product returns history of XENLETA returns, the Company estimated returns based on industry data for comparable products in the market. As the Company distributes its product and establishes historical sales over a longer period of time (i.e., two to three years), the Company will be able to place more reliance on historical purchasing, demand and return patterns of its customers when evaluating its reserves for product returns. The Company’s XENLETA product has a thirty-six-month shelf life. their customers demand, product returns could increase in excess of what the Company has currently reserved which would result in a reduction to net revenues in future periods. ​ At the end of each reporting period for any of its products, the Company may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of product currently being shipped, price changes of competitive products and introductions of generic products. Chargebacks and rebates – Although the Company primarily sells products to specialty distributors in the United States, the Company also enters into agreements with hospitals and retail pharmacies, either directly or through group purchasing organizations acting on behalf of their members, in connection with the purchase of product. Based on these agreements, certain of the Company’s customers have the right to receive a discounted price on product purchases. The Company typically provides a credit to its specialty distributors customers (i.e., chargeback), representing the difference between the customer’s acquisition list price and the discounted price. The calculation of the accrual for chargebacks and rebates is based on estimates of claims and their associated cost that the Company expects to receive associated with product sales that have been recognized as revenue but remain in the distribution channel as inventory at the end of each reporting period. Government rebates –The Company is subject to discount obligations primarily under state Medicaid and Medicare programs. The Company estimates its Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payer mix. These reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The calculation of the accrual for government rebates is based on estimates of claims and their associated cost that the Company expects to receive associated with product sales that have been recognized as revenue but remain in the distribution channel as inventory at the end of each reporting period. Commercial payer and other rebates – The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of XENLETA and contracted formulary status. The Company estimates these rebates and records reserves for such estimates in the same period the related revenue is recognized. Currently, the reserve for customer payer rebates considers future utilization based on third party studies of payer prescription data; the utilization is applied to product that remains in the distribution and retail pharmacy channel inventories at the end of each reporting period. The calculation of the accrual for commercial payer and other rebates is based on estimates of claims and their associated cost that the Company expects to receive associated with product sales that have been recognized as revenue but remain in the distribution channel as inventory at the end of each reporting period. GPO administration fees – The Company contracts with GPOs and pays administration fees related to contacting and membership management services provided. In assessing if the consideration paid to the GPO should be recorded as a reduction in the transaction price, the Company determines whether the payment is for a distinct good or service or a combination of both. Since GPO fees are not specifically identifiable, the Company does not consider the fees separate from the purchase of the product. Additionally, the GPO services generally cannot be provided by a third party. Because of these factors, the consideration paid is considered a reduction of revenue. Patient assistance At the end of each reporting period, the Company will adjust its variable consideration estimates for product returns, chargebacks, and rebates when the Company believes actual experience may differ from current estimates. The following table summarizes balances and activity of product revenue allowances and reserves: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2019 ​ 2020 Balance at January 1 ​ $ — ​ $ 534 Provision related to current period sales ​ 635 ​ 182 Adjustment related to prior period sales ​ — ​ 194 Credit or payments made during the period ​ (101) ​ (248) Balance at December 31 ​ $ 534 ​ $ 662 ​ Cost of Product Sales Cost of product sales primarily represents direct and indirect manufacturing costs of XENLETA. Prior to the FDA approval of XENLETA on August 19, 2019, the inventory costs for the product were expensed as research and development expenses since the approval was outside of the Company’s control and therefore not considered probable. As such, the majority of the expenses incurred for initial inventories of XENLETA has been previously expensed. For the year ended December 31, 2020 the cost of product sales includes a $0.7 million non-cash reserve for excess and obsolete inventory due to the uncertainty of commercial activities underlying XENLETA sales. ​ Research Premium and Grant Revenue Grant revenue comprises (a) the research premium from the Austrian government, (b) grants received from the Austrian Research Promotion Agency ( Österreichische Forschungsförderungsgesellschaft, or FFG The research premium the Company receives from the Austrian government is calculated at a specified percent of specified research and development cost base. The Company recognizes the research premium as long as it has incurred research and development expenses. All grants are non-refundable as long as the conditions of the grant are met. Nabriva is and has been in full compliance with the conditions of the grants and all related regulations. Research and Development Expenses All research and development costs are expensed as incurred. Research and development costs included direct personnel and material costs, related overheads, depreciation of equipment used for research or development purposes; costs for clinical research; costs for the utilization of third parties’ patents for research and development purposes and other taxes related to research facilities. Share-based Payments The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award in accordance with ASC 718, Compensation — Stock Compensation Leases In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases the previous lease standard in its annual disclosures for the comparative periods. In addition, the new lease standard provides a number of optional practical expedients in transition. The Company elected the package of practical expedients. As such, the Company did not have to reassess whether expired or existing contracts are or contain a lease; and did not have to reassess the lease classifications or reassess the initial direct costs associated with expired or existing leases. The new lease standard also provides practical expedients for an entity's ongoing accounting. The Company elected the short-term lease recognition exemption under which the Company will not recognize right of use, or ROUassets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases. The Company elected the practical expedient to not separate lease and non-lease components for certain classes of assets (office buildings). The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease ROU assets, other current liabilities, and operating lease liabilities on the Company’s consolidated balance sheet. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the remaining lease term. Since none of the Company’s lease agreements provide an implicit rate, the Company estimated an incremental borrowing rate over the lease term based on the information available at January 1, 2020 in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as operating costs and property taxes are expensed as incurred. On January 1, 2019, the Company recognized ROU assets and lease liabilities property, plant and equipment ROU liability December 31, 2020 ​ Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. In recognizing the benefit of tax positions, the Company has taken or expects to take, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company’s policy is to record interest and penalties related to tax matters in income tax expense. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Adopted as of the current period: Customer’s Accounting for Implementation Cost Incurred in a Cloud Computing Arrangement That Is a Service Contract

Short-term investments

Short-term investments	12 Months Ended
	Dec. 31, 2020
Short-term investments
Short-term investments	3. Short-term investments The Company’s short-term investments were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Term deposits ​ $ 16 ​ $ — ​ $ — ​ $ 16 Total ​ $ 16 ​ $ — ​ $ — ​ $ 16 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2019 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Term deposits ​ ​ 175 ​ ​ — ​ ​ — ​ ​ 175 Total ​ $ 175 ​ $ — ​ $ — ​ $ 175 ​ As of December 31, 2020 and 2019, the Company’s short-term investments were classified as available-for-sale and comprised of certain term deposits with maturities in excess of 90 days.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2020
Fair Value Measurement
Fair Value Measurement	4. Fair Value Measurement US GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: ● Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. ● Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (as exchange rates). ● Level 3: Valuation techniques that include inputs for the asset or liability that are not based on observable market data (those are unobservable inputs) and significant to the overall fair value measurement. The following table presents the financial instruments measured at fair value and classified by level according to the fair value measurement hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Total December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalent: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market fund ​ $ 8,050 ​ $ — ​ $ — $ 8,050 Short term investments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Term deposits ​ ​ 16 ​ ​ — ​ ​ — ​ 16 Total Assets ​ $ 8,066 ​ $ — ​ $ — $ 8,066 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Total December 31, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalent: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market fund ​ $ 15,050 ​ $ — ​ $ — $ 15,050 Short term investments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Term deposits ​ 175 ​ — ​ — ​ 175 Total Assets ​ $ 15,225 ​ $ — ​ $ — $ 15,225 ​ There were no transfers between Level 1 and 2 in the years ended December 31, 2020 and 2019. There were no changes in valuation techniques during the years ended December 31, 2020 and 2019. As of December 31, 2020 and 2019, the Company did not hold any financial instruments as liabilities that were held at fair value.

Accounts receivable, net and ot

Accounts receivable, net and other receivables	12 Months Ended
	Dec. 31, 2020
Accounts receivable, net and other receivables
Accounts receivable, net and other receivables	5. Accounts receivable, net and other receivables ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31 (in thousands) 2019 2020 Receivables from collaborative arrangments ​ $ — ​ $ 2,426 Research premium ​ ​ 1,530 ​ ​ 1,308 Other receivables ​ 1,214 ​ 175 Total accounts receivable, net and other receivables ​ $ 2,744 ​ $ 3,909 ​

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment
Property, Plant and Equipment	6. Property, Plant and Equipment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31 (in thousands) 2019 2020 IT equipment ​ $ 1,060 ​ $ 1,077 Laboratory equipment ​ 3,375 ​ 3,392 ROU asset ​ ​ 1,647 ​ ​ 226 Other equipment ​ 165 ​ 204 ​ ​ ​ 6,247 ​ ​ 4,899 Less: Accumulated depreciation ​ ​ (3,773) ​ ​ (4,131) Property, plant and equipment, net ​ $ 2,474 ​ $ 768 ​

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2020
Accrued Expenses and Other Current Liabilities
Accrued Expenses and Other Current Liabilities	7. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities include the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands) 2019 2020 Research and development related costs ​ $ 1,347 ​ $ 1,055 Payroll and related costs ​ 6,327 ​ 4,049 Accounting, tax and audit services ​ 420 ​ 470 Manufacturing and inventory ​ ​ 639 ​ ​ 4,779 Accrued gross to net ​ ​ 534 ​ ​ 662 Other ​ 2,699 ​ 1,829 Total other current liabilities ​ $ 11,966 ​ $ 12,844 ​

Debt

Debt	12 Months Ended
	Dec. 31, 2020
Debt
Debt	8. Debt In December 2018, the Company entered into the Loan Agreement by and among the Company, Nabriva Therapeutics Ireland DAC, and certain other subsidiaries of the Company and Hercules Capital, Inc., or Hercules, pursuant to which a term loan of up to an aggregate principal amount of $75.0 million was available to the Company. The Loan Agreement initially provided for an initial term loan advance of $25.0 million, which was funded in December 2018, and, at the Company’s option and subject to the occurrence of certain funding conditions, several additional tranches of which $5.0 million became available upon the approval by the FDA of the NDA for XENLETA, which was drawn down. The other tranches are no longer available as their contingencies were not achieved. The Company may request a term loan advance of $5.0 million prior to December 31, 2021 subject to Hercules’s sole discretion. The term loan bears interest at an annual rate equal to the greater of 9.80% or 9.80% plus the prime rate of interest minus 5.50%. The Loan Agreement provided for interest-only payments through July 1, 2021 and repayment of the outstanding principal balance of the term loan thereafter in monthly installments through June 1, 2023 (the “Maturity Date”). In addition, the Company is required to pay a fee of 6.95% of the aggregate amount of advances under the Loan Agreement at the Maturity Date (the “End of Term Fee”). At the Company’s option, the Company may elect to prepay any portion of the outstanding term loan that is greater than or equal to $5.0 million by paying such portion of the principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) 3.0% if the term loan is prepaid during the first 12 months following the initial closing, (ii) 2.0% if the term loan is prepaid after 12 months following the initial closing but before 24 months following the initial closing and (iii) 1.0% if the term loan is prepaid any time thereafter but prior to the Maturity Date. On March 11, 2020, the Company entered into an amendment (the “Amendment”), to its Loan Agreement with Hercules. Pursuant to the Amendment, the Company repaid $30.0 million of the $35.0 million in aggregate principal amount of debt outstanding under the Loan Agreement (the “Prepayment”). The Company determined to enter into the Amendment following the effectiveness of a performance covenant in February 2020 under which it became obligated to either (1) achieve 80% of its net product revenue sales target over a trailing six-month period, or (2) maintain an amount of cash and cash equivalents in accounts pledged to Hercules plus a specified amount of eligible accounts receivables equal to the greater of the amount outstanding under the Loan Agreement or $40.0 million (the “Liquidity Requirement”). Under the Amendment, the Company and Hercules agreed to defer the end of term loan charge payment of $2.1 million that would have otherwise become payable on the date of the Prepayment and to reduce the prepayment charge with respect to the Prepayment from $600,000 to $300,000 and to defer its payment, in each case, until June 1, 2023 or such earlier date on which all loans under the Loan Agreement are repaid or become due and payable. The Amendment also reset the revenue performance covenant to 70% of targeted revenue based on a revised net product revenue forecast and lowered the minimum liquidity requirement to $3.0 million in cash and cash equivalents, in each case, following the Prepayment. The new minimum liquidity requirement will not apply if CONTEPO receives regulatory approval from the U.S. Food and Drug Administration and the Company achieves at least 70% of its revised net product revenue targets under the Loan Agreement. The Company was in compliance with all of its Loan Agreement covenants at December 31, 2020. The Company’s obligations under the Loan Agreement are guaranteed by all current and future subsidiaries of the Company, and each of the Company and its subsidiaries has granted Hercules a security interest in all of their respective personal property, intellectual property and other assets owned or later acquired. The Loan Agreement also contains certain events of default, representations, warranties and covenants of the Company and its subsidiaries. For example, the Loan Agreement contains representations and covenants that, subject to exceptions, restrict the Company’s and its subsidiaries’ ability to do the following, among other things: declare dividends or redeem or repurchase equity interests; incur additional indebtedness and liens; make loans and investments; engage in mergers, acquisitions and asset sales; certain transactions with affiliates; undergo a change in control; and add or change business locations or settle in cash potential milestone payment obligations that may become payable by the Company in the future to former security holders of Zavante. ​ The Loan Agreement also grants Hercules or its nominee an option to purchase up to an aggregate of $2.0 million of the Company’s equity securities, or instruments exercisable for or convertible into equity securities, sold to investors in any private financing upon the same terms and conditions afforded to such other investors for as long as there are amounts outstanding under the Loan Agreement. The Company incurred $1.3 million of costs in connection with the Loan Agreement which along with the initial fee of $0.7 million paid to Hercules were recorded as debt issuance cost and are being amortized as interest expense using the effective interest method over the term of the loan. In connection with the Amendment, the Company recognized a non-cash $2.7 million loss on the extinguishment of debt during 2019 which represents the excess of the reacquisition price of the $30.0 million debt repaid over the net carrying amount of the extinguished debt. The carrying value of the term loan payable at December 31, 2020 includes the present value of the End of Term Fee and the Prepayment Fee. The End of Term Fee on the remaining $5.0 million principal balance is being accrued as additional interest expense using the effective interest method over the term of the loan. Long-term debt as December 31, 2019 and 2020 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands) 2019 2020 Term loan payable $ 35,000 $ 5,000 End of term fee ​ ​ 443 ​ ​ 2,048 Unamortized debt issuance costs ​ (1,742) ​ (206) Carrying value of term loan ​ ​ 33,701 ​ ​ 6,842 Other long-term debt ​ ​ 801 ​ ​ 885 Less: Amounts due within one year ​ ​ — ​ ​ (2,041) Total long-term debt $ 34,502 $ 5,686 ​ As of December 31, 2020, the maturities of our long-term debt were as follows: ​ ​ ​ ​ ​ (in thousands) ​ ​ ​ 2021 $ 2,041 2022 ​ 2,493 2023 ​ ​ 4,084 ​

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity
Stockholders' Equity	9. Stockholders’ Equity In December 2020, the Company completed a registered public offering in which it sold 6,000,000 ordinary shares at a public offering price of $2.50. The proceeds to the Company from the offering were $15.0 million gross and $13.3 million net, after deducting the placement agent’s fees and other offering expenses. In May 2020, the Company sold to certain institutional investors, including Fidelity Management & Research Company, LLC, in a registered direct offering an aggregate of 4,144,537 ordinary shares and accompanying warrants to purchase up to an aggregate of 4,144,537 ordinary shares at a combined price of $9.1686 per security. The proceeds to the Company from the offering were $38.0 million gross and $35.2 million net, after deducting the placement agent’s fees and other offering expenses. As of December 31, 2020, there were 4,059,532 warrants outstanding, where each warrant has an exercise price of $7.92 per share and is immediately exercisable and will expire on the two-year anniversary of the issuance date. ​ In December 2019, the Company sold to certain institutional investors in a registered direct offering an aggregate of 1,379,310 ordinary shares, and accompanying warrants to purchase up to an aggregate of 1,379,310 ordinary shares. Each share was issued and sold together with an accompanying warrant at a combined price of $14.50 per security. The proceeds to the Company from the offering were $20.0 million gross and $18.3 million net, after deducting the placement agent’s fees and other offering expenses. As of December 31, 2020, there were 1,379,310 warrants outstanding, where each warrant has an exercise price of $19.00 per share and is initially exercisable six months following the date of issuance, or the Initial Exercise Date, and will expire on the three-year anniversary of the Initial Exercise Date. SM In July 2018, the Company completed an underwritten public offering and issued 1,818,181 ordinary shares at a public offering price of $27.50 per share, resulting in gross proceeds of $50.0 million and net proceeds to the Company of $46.3 million, after deducting underwriting discounts and commissions and offering expenses. In March 2018, the Company entered into a Controlled Equity Offering SM

Revenue

Revenue	12 Months Ended
	Dec. 31, 2020
Revenue
Revenue	10. Revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands) 2018 2019 2020 Product revenue, net ​ $ — ​ $ 1,538 ​ $ 108 Collaboration revenues ​ ​ 6,500 ​ ​ 6,210 ​ ​ 2,756 Research premium ​ ​ 2,594 ​ ​ 1,311 ​ ​ 1,227 Government grants ​ 562 ​ 422 ​ 936 Total ​ $ 9,656 ​ $ 9,481 ​ $ 5,027 ​ ​ Collaboration revenues for the year ended December 31, 2019 includes a $1.0 million upfront payment under the Sunovion License Agreement received in April 2019, and a $5.0 million milestone payment under the Sinovant License Agreement (see Note 16). Collaboration revenues for the year ended December 31, 2020 includes a $0.5 million regulatory milestone payment from Sunovion, $1.8 million for the Company´s share of revenues associated with the SIVEXTRO distribution agreement with Merck & Co., Inc., as well as collaboration revenues associated with the restructuring of the Company´s license agreement with Sinovant. The Company will recognize the $1.0 million payment received as collaboration revenue in the consolidated statements of operations over the estimated period the manufacturing collaboration and regulatory support will be provided to Sinovant. The Company sells its products to pharmaceutical wholesalers/distributors (i.e. the Company´s customers). The Company´s wholesalers/distributors in turn sell the Company´s products directly to clinics, hospitals, and private practices. Revenue from the Company´s product sales is recognized as physical delivery of product occurs (when the Company´s customer obtains control of the product), in return for agreed-upon consideration. ​ For the year ended December 31, 2020 product revenues, gross were $0.5 million, respectively. The Company´s product revenues, gross (i.e., delivered units multiplied by the contractual price per unit) are reduced by the corresponding gross-to-net, or GTN, estimates, resulting in the Company´s reported “product revenues, net” in the accompanying consolidated statements of operations. These GTN estimates are based upon information received from external sources (such as written or oral information obtained from the Company´s customers with respect to their period-end inventory levels and sales to end-users during the period), in combination with management’s informed judgments. Due to the inherent uncertainty of these estimates, the actual amount incurred may be materially above or below the amount initially estimated when product revenues are originally recorded, then requiring prospective adjustments to our reported product revenues, net. ​ The following tables summarizes GTN adjustments for the periods presented: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, (in thousands) 2019 2020 Product revenue, gross $ 2,173 $ 484 GTN accruals ​ ​ ​ ​ ​ ​ Chargebacks and cash discounts ​ 48 ​ 16 Medicaid and Medicare rebates ​ ​ 223 ​ ​ 52 Other returns, rebates, discounts and adjustments ​ ​ 364 ​ ​ 115 Total GTN accruals ​ ​ (635) ​ ​ (183) Product revenue ​ ​ 1,538 ​ ​ 301 Adjustments to prior period accruals ​ ​ ​ ​ ​ ​ Returns reserve (1) ​ ​ — ​ ​ (421) GTN accrual adjustments ​ ​ — ​ ​ 228 Product revenue, net $ 1,538 $ 108 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) As of December 31, 2020, the Company recorded a returns reserve adjustment for slow-moving inventory, representing 50% of XENLETA IV inventory held at its Specialty Distributors, as well as an adjustment for returns from a single mail order specialty pharmacy.

Share-Based Payments

Share-Based Payments	12 Months Ended
	Dec. 31, 2020
Share-Based Payments
Share-Based Payments	11. Share-Based Payments Stock Option Plan 2015 On April 2, 2015, the Company’s shareholders, management board and supervisory board adopted the Stock Option Plan 2015, or the SOP 2015, as amended. With the approval of the 2017 Share Incentive Plan, there were no further options are available for grant under the SOP 2015. However, all outstanding awards under SOP 2015 will remain in effect and continue to be governed by the terms of the SOP 2015. Each vested option grants the beneficiary the right to acquire one share in the Company. The vesting period for the options is four years following the grant date. On the last day of the last calendar month of the first year of the vesting period, 25% of the options attributable to each beneficiary are automatically vested. During the second, third and fourth years of the vesting period, the remaining 75% of the options vest on a monthly pro rata basis (i.e. 2.083% per month). Options granted under the SOP 2015 have a term of no more than ten years from the beneficiary’s date of participation. The following table summarizes information regarding the Company´s stock option awards under the SOP 2015: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2018 ​ 2019 ​ 2020 ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ ​ ​ ​ exercise ​ ​ ​ exercise ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in ​ ​ ​ price in ​ ​ ​ price in ​ intrinsic Stock Option Plan 2015 ​ Options $ per share ​ Options $ per share Options $ per share value Outstanding as of January 1, ​ 304,489 ​ 83.54 ​ 284,291 83.41 ​ 229,060 ​ 83.27 ​ Granted ​ — ​ — ​ — — ​ — ​ — ​ ​ Exercised ​ — ​ — ​ — — ​ — ​ — ​ ​ Forfeited ​ (20,198) ​ 84.07 ​ (55,231) 84.01 ​ (26,686) 87.46 ​ ​ Outstanding as of December 31, ​ 284,291 83.41 ​ 229,060 83.27 202,374 ​ 82.71 ​ $ — Vested and exercisable as of December 31, ​ 184,459 80.97 ​ 198,491 81.98 198,574 82.51 ​ $ — ​ The Company has 202,374 option grants outstanding at December 31, 2020 with exercise prices ranging from $40.60 per share to $110.00 per share and a weighted average remaining contractual life of 5.4 years. Stock-based compensation expense under the SOP 2015 was $3.2 million, $4.0 million and $1.1 million for the years ended December 31, 2018, 2019 and 2020, respectively. As of December 31, 2020, there was $0.2 million of unrecognized compensation expense, related to unvested options granted under the SOP 2015 Plan, which will be recognized over the weighted average remaining vesting period of 0.2 years. 2017 Share Incentive Plan On July 26, 2017, the Company’s board of directors adopted the 2017 Share Incentive Plan, or the 2017 Plan, and the shareholders approved the 2017 Plan at the Company’s Extraordinary General Meeting of Shareholders on September 15, 2017. Following shareholder approval of the 2017 Plan, the Company ceased making awards under the SOP 2015. The 2017 Plan permited the award of share options (both incentive and nonstatutory options), share appreciation rights, or SARs, restricted shares, restricted share units, or RSUs, and other share-based awards to the Company’s employees, officers, directors, consultants and advisers. The 2017 Plan is administered by the Company’s board of directors. With the approval of the 2020 Share Incentive Plan, there were no further options are available for grant under the 2017 Plan. ​ The following table summarizes information regarding our stock option awards under the 2017 Plan at December 31, 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2018 ​ 2019 ​ 2020 ​ ​ ​ ​ ​ Weighted ​ ​ Weighted ​ ​ Weighted ​ ​ ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ ​ ​ exercise ​ ​ ​ exercise ​ ​ ​ exercise ​ ​ Aggregate ​ ​ ​ price in $ ​ ​ ​ price in $ ​ ​ ​ price in $ ​ ​ intrinsic 2017 Plan Options per share ​ Options per share Options per share ​ value Outstanding as of January 1, 29,410 ​ 69.17 ​ 239,842 ​ 54.14 442,266 ​ 35.48 Granted 219,922 ​ 52.71 ​ 246,330 ​ 19.51 129,050 ​ 13.50 Exercised — ​ — ​ — ​ — — ​ — Forfeited (9,490) ​ 67.52 ​ (43,906) ​ 47.87 (128,472) ​ 29.39 ​ ​ Outstanding as of December 31, 239,842 ​ 54.14 ​ 442,266 ​ 35.48 442,844 ​ 30.89 ​ $ — Vested and exercisable as of December 31, 11,928 ​ 68.77 ​ 112,028 ​ 55.33 228,731 ​ 39.02 ​ $ — ​ The Company has 442,844 option grants outstanding at December 31, 2020 with exercise prices ranging from $13.50 per share to $81.90 per share and a weighted average remaining contractual life of 8.2 years. Stock-based compensation expense for stock options granted under the 2017 Plan was $1.8 million, $2.6 million and $2.0 million for the years ended December 31, 2018, 2019 and 2020, respectively. The weighted average fair value of the options granted during years ended December 31, 2018, 2019 and 2020 was $30.64, $11.38 and $7.97 per share, respectively, based on a Black Scholes option pricing model using the following assumptions: ​ ​ ​ ​ ​ ​ ​ Input parameters 2018 2019 2020 Range of expected volatility 59.8% - 61.4% 61.4% - 63.1% 63.8% - 64.0% Expected term of options (in years) 6.1 6.0 6.1 Range of risk-free interest rate 2.6% - 3.0% 1.9% - 2.6% 0.8% - 1.5% Dividend yield — – — ​ The expected price volatility is based on historical trading volatility for the publicly traded peer companies under consideration of the remaining life of the options. The risk-free interest rate is based on the average of five and seven-year market yield on U.S. treasury securities in effect at the time of grant. As of December 31, 2020, there was $2.6 million of total unrecognized compensation expense, related to unvested options granted under the 2017 Plan, which will be recognized over the weighted-average remaining vesting period of 0.9 years. Restricted Stock Units, or RSUs Under the 2017 Plan, the Company granted RSUs which vest over a period of four years with 25% vesting upon the first anniversary of the grant date and on a monthly pro rata basis thereafter over the remaining three years. The Company also granted RSUs to certain employees that vest over a period of four years with 25% vesting upon the first anniversary of the grant date and on a monthly pro rata basis thereafter over the remaining three years. During 2018, the Company granted RSUs to certain employees where vesting of the RSUs was subject to FDA approval of an NDA for XENLETA. Fifty percent (50%) of each RSU award vested upon FDA approval, and the remaining fifty percent (50%) will vest on the one- year anniversary of such approval. In connection with the FDA approval that was received in August 2019, the Company started recognizing compensation expense, as there was no compensation expense recognized on these awards prior to the FDA approval as it was determined that approval was not probable since it was outside of the Company’s control. Also during 2018, the Company granted RSUs to certain employees that have vested in three six-month increments beginning in May 2019 and ending in May 2020. Lastly, the Company granted RSUs in 2018 to certain employees where vesting of the RSUs is subject to FDA approval of an NDA for CONTEPO. Fifty percent (50%) of each RSU award will vest upon FDA approval, and the remaining fifty percent (50%) will vest on the one-year anniversary of such approval. The following table summarizes information regarding our restricted stock unit awards under the 2017 Plan at December 31, 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2019 ​ 2020 ​ ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ average fair ​ ​ ​ average fair 2017 Plan RSUs ​ value in $ per share ​ RSUs ​ value in $ per share Outstanding as of January 1, 122,210 ​ 33.10 ​ 90,169 ​ 27.37 Granted 47,900 ​ 19.00 ​ 155,730 ​ 13.50 Vested and issued (65,758) ​ 31.80 ​ (51,671) ​ 30.95 Forfeited (14,183) ​ 27.87 ​ (42,959) ​ 17.23 Outstanding as of December 31, 90,169 ​ 27.37 ​ 151,269 ​ 14.56 ​ ​ ​ As of December 31, 2020, there was unrecognized compensation costs of $1.3 million associated with RSUs which are expected to be recognized over the awards average remaining vesting period of 1.1 years. The fair value of RSU’s that vested during the years ended December 31, 2019 and 2020 was $2.1 million and $1.7 million, respectively. ​ 2019 Inducement Share Incentive Plan On March 12, 2019, the Company’s board of directors adopted the 2019 Inducement Share Incentive Plan, or the 2019 Inducement Plan and, subject to the adjustment provisions of the 2019 Inducement Plan, reserved 200,000 ordinary shares for issuance pursuant to equity awards granted under the 2019 Inducement Plan. In accordance with Nasdaq Listing Rule 5635(c)(4), awards under the 2019 Inducement Plan may only be made to individuals who were not previously employees or non-employee directors of the Company (or following such individuals’ bona fide period of non-employment with the Company), as an inducement material to the individuals’ entry into employment with the Company. On April 28, 2020, the board of directors resolved not to make any further awards under the 2019 Inducement Plan. The following table summarizes information regarding the Company’s stock option awards under the 2019 Inducement Plan for the years ended December 31, 2019 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2019 ​ 2020 ​ ​ ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ ​ ​ exercise ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in $ ​ ​ ​ price in $ ​ intrinsic 2019 Inducement Plan Options per share Options per share value Outstanding as of January 1 — ​ — 60,565 ​ 21.45 Granted 70,315 ​ 22.20 18,200 ​ 13.50 Exercised — — — ​ — Forfeited (9,750) ​ 26.92 (52,950) ​ 19.59 Outstanding as of December 31 60,565 ​ 21.45 25,815 ​ 19.04 ​ — Vested and exercisable as of December 31 — ​ — 4,396 ​ 26.96 ​ — ​ ​ Stock-based compensation expense under the 2019 Inducement Plan was $77,000 and $38,000 for the years ended December 31, 2019 and 2020, respectively. The weighted average fair value of the options granted during the years ended December 31, 2019 and 2020 was $13.04 and $7.93 per share, respectively. The options granted during the year ended December 31, 2020 were valued based on a Black Scholes option pricing model using the following assumptions. The significant inputs into the model were as follows: ​ ​ ​ ​ ​ ​ ​ Input parameters 2019 ​ 2020 Range of expected volatility 59.8% - 61.4% ​ 63.7% - 64.0% Expected term of options (in years) 6.1 ​ 6.1 Range of risk-free interest rate 2.55% - 3.03% ​ 0.96% - 1.37% Dividend yield – ​ – ​ The Company has 25,815 option grants outstanding at December 31, 2020 with exercise prices ranging from $13.50 per share to $29.90 per share and a weighted average remaining contractual life of 8.7 years. As of December 31, 2020, there was $0.2 million of total unrecognized compensation expense, related to unvested options granted under the 2019 Inducement Plan, which will be recognized over the weighted-average remaining vesting period of 1.2 years. ​ Inducement Awards Outside of the 2019 Inducement Plan In July 2018, the Company granted a non-statutory option to purchase 85,000 of its ordinary shares and 15,000 performance-based RSUs to the Company’s newly appointed Chief Executive Officer, or the CEO. These equity awards were granted outside of the 2017 Plan, were approved by the Company’s compensation committee and board of directors and were made as an inducement material to the CEO entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price per share for the share option is $35.30 per share, and the option award has a ten-year term and will vest over a four-year period, with 25% of the shares underlying the award vesting on the first anniversary of the grant date and the remaining 75% of the shares underlying the option award to vest monthly over the subsequent 36-month period. The performance-based RSUs are subject to vesting as follows: 50% will vest upon certification by the board of directors of the receipt of approval by the FDA of an NDA for each of lefamulin and CONTEPO for any indication, and 50% will vest on the first anniversary of such certification by the board of directors, provided, in each case, the CEO is performing services to the Company on the applicable vesting dates. If the FDA does not approve an NDA for both lefamulin and CONTEPO by January 31, 2020, the performance-based RSUs will terminate in full. Since CONTEPO was not approved by this date the award was forfeited. The Company also issues non-statutory options to new employees upon the commencement of their employment. Stock-based compensation expense was $0.4 million and $0.4 million for the year ended December 31, 2019 and December 31, 2020. The performance-based RSUs granted to our CEO, had a grant date fair value of $35.30 per share (although no expense was recognized as FDA approval was not considered probable) and the options granted to our CEO had a grant date fair value of $20.50 per share based on a Black Scholes option pricing model using the following assumptions. ​ ​ ​ ​ ​ Input parameters ​ ​ Expected volatility 59.8 % Expected term of options (in years) 6.1 ​ Range of risk-free interest rate 2.9 % Dividend yield — ​ ​ The weighted average remaining contractual life of the options as of December 31, 2020 is 7.6 years. As of December 31, 2020, there was $0.7 million of total unrecognized compensation expense, related to unvested inducement award options granted, which will be recognized over the weighted-average remaining vesting period of 0.8 years. 2020 Share Incentive Plan On March 4, 2020, the Company´s board of directors adopted the 2020 Share Incentive Plan, or the 2020 Plan, which was approved by the Company´s shareholders at the 2020 Annual General Meeting of Shareholders in July 2020, or 2020 AGM. As of the date of the 2020 AGM, the total number of ordinary shares reserved for issuance under the 2020 Plan was for the sum of 930,000 ordinary shares, plus the number of the Company´s ordinary shares that remained available for grant under the 2017 Plan as of immediately prior to the AGM and the number of ordinary shares subject to awards granted under the 2017 Plan and the Company´s Amended and Restated Stock Option Plan 2015, that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right. Following shareholder approval of the 2020 Plan, no further awards will be made under the 2017 Plan. The 2020 Plan provides for the grant of incentive share options, non-statutory share options, share appreciation rights, restricted share awards, restricted share units, other share-based and cash-based awards and performance awards. At The following table summarizes information regarding the Company’s stock option awards under the 2020 Plan for the year ended December 31, 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in $ ​ intrinsic 2020 Plan Options per share value Outstanding as of January 1, — ​ — Granted 317,805 ​ 10.24 Exercised — ​ — Forfeited (21,000) ​ 7.88 Outstanding as of December 31, 296,805 ​ 10.18 ​ — Vested and exercisable as of December 31, — ​ — ​ — ​ ​ Stock-based compensation expense under the 2020 Plan was $144,000 for the year ended December 31, 2020. The weighted average fair value of the options granted during the year ended December 31, 2020 was $4.40 per share. The options granted in the year ended December 31, 2020 were valued based on a Black Scholes option pricing model using the following assumptions. The significant inputs into the model were as follows: ​ ​ ​ ​ Input parameters 2020 Expected volatility 73.0% - 74.4% Expected term of options (in years) 5.5 - 6.1 Risk-free interest rate 0.34% - 0.51% Dividend yield — ​ The Company has 296,805 option grants outstanding at December 31, 2020 with exercise prices ranging from $2.42 per share to $13.50 per share and a weighted average remaining contractual life of 9.6 years. As of December 31, 2020, there was $1.3 million of total unrecognized compensation expense related to unvested options granted under the 2020 Plan, which will be recognized over the weighted-average remaining vesting period of 1.6 years. Restricted Stock Units, or RSUs During 2020, the Company granted 45,977 RSUs to certain employees that vest in three six-month increments beginning in January 2021 and ending in January 2022, with a grant date fair value of $7.88 per share. Also during 2020, the Company granted 43,125 RSUs to certain employees with a grant date fair value of $5.30 per share, where vesting of the RSUs was subject to individual performance goals. For the year ended December 31, 2020, stock-based compensation expense of $111,000 was recognized for these RSUs. As of December 31, 2020, there was $0.5 million of unrecognized compensation expense related to unvested RSUs, which will be recognized over the weighted-average remaining vesting period of 1.0 years. Our share-based compensation expense has been allocated to research and development and selling, general and administrative expenses in the consolidated statement of operations as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands) 2018 2019 2020 Research and development ​ $ 1,406 ​ $ 2,138 ​ $ 1,280 Selling, general and administrative ​ 3,748 ​ 7,610 ​ 3,939 Total ​ $ 5,154 ​ $ 9,748 ​ $ 5,219 ​ The Company recognizes the impact of forfeitures as they occur and issues new shares to satisfy share based compensation arrangements upon the exercise of stock options or vesting of restricted shares. ​ Employee Stock Purchase Plan The Company’s board of directors adopted, and in August 2018 Company’s stockholders approved, the 2018 employee stock purchase plan, or the 2018 ESPP. The maximum aggregate number of shares of ordinary shares that may be purchased under the 2018 ESPP is 50,000 shares, or the ESPP Share Pool, subject to adjustment as provided for in the 2018 ESPP. The ESPP Share Pool available as of December 31, 2020, represented less than 0.1% of the total number of shares of ordinary shares outstanding as of December 31, 2020. The 2018 ESPP allows eligible employees to purchase shares at a 15% discount to the lower of the closing share price at the beginning and end of the six-month offering periods commencing November 1 and ending April 30 and commencing May 1 and ending October 31 of each year. As of the date of this filing, the Company has suspended the 2018 ESPP until further notice.

Post-employment benefit obligat

Post-employment benefit obligations	12 Months Ended
	Dec. 31, 2020
Post-employment benefit obligations
Post-employment benefit obligations	12. Post-employment benefit obligations As required under Austrian labor law, the Company makes contributions to a state plan classified as defined contribution plan (Mitarbeitervorsorgekasse) for its employees in Austria. Monthly contributions to the plan are 1.53% of salary with respect to each employee and are recognized as expense in the period incurred. For employees of Nabriva Therapeutics US, Inc., the Company makes contributions to a defined contribution plan as defined in subsection 401(k) of the Internal Revenue Code. The Company matches 100% of the first 3% of the employee’s voluntary contribution to the plan and 50% of the next 2% contributed by the employee. Contributions are recognized as expense in the period incurred. In the years ended December 31, 2018, 2019 and 2020, contributions were $448,000, $710,000 and $396,000, respectively.

Income tax expense

Income tax expense	12 Months Ended
	Dec. 31, 2020
Income tax expense
Income tax expense	13. Income tax expense Income (loss) before income taxes attributable to domestic and international operations, consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 (in thousands) 2018 2019 2020 Domestic ​ $ (113,699) ​ $ (78,761) ​ $ (71,344) Foreign ​ (1,032) ​ (3,902) ​ 1,999 Loss before income taxes ​ $ (114,731) ​ $ (82,663) ​ $ (69,345) ​ Income tax expense consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 (in thousands) 2018 2019 2020 Current tax ​ ​ ​ ​ ​ ​ ​ ​ ​ Domestic ​ $ — ​ $ — ​ $ — Foreign ​ (49) ​ (101) ​ (139) Deferred tax ​ ​ ​ ​ ​ ​ ​ ​ ​ Domestic ​ — ​ — ​ — Foreign ​ — ​ — ​ — Total income tax expense ​ $ (49) ​ $ (101) ​ $ (139) ​ The reconciliation to our effective tax rate from the Irish statutory income tax rate of 12.5% for the years ended December 31, 2018, 2019 and 2020 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 ​ (% of pre-tax income) 2018 2019 2020 ​ Statutory income tax rate 12.5 % 12.5 % 12.5 % Non-deductible expenses (0.1) ​ (0.1) ​ — ​ Income not subject to tax 0.3 ​ 0.3 ​ 0.2 ​ Tax credits 0.1 ​ 0.4 ​ 0.6 ​ Foreign rate differential (3.1) ​ 0.6 ​ 3.0 ​ In-process research and development ​ (3.5) ​ — ​ — ​ Tax audit assessments — ​ (11.8) ​ — ​ Other ​ 0.2 ​ 0.8 ​ 2.3 ​ Valuation allowance (6.5) ​ (2.8) ​ (18.8) ​ Effective income tax rate (0.1) % (0.1) % (0.2) % ​ The following table summarizes the components of deferred income tax balances: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands) 2019 2020 Deferred tax assets: ​ ​ ​ ​ Net operating loss carryforwards ​ $ 94,014 ​ $ 108,095 Tax loss on liquidation of subsidiary ​ ​ 5,024 ​ ​ 4,029 Equity compensation ​ 4,182 ​ 4,449 Non-deductible reserves ​ 395 ​ 447 Total deferred tax assets ​ ​ 103,615 ​ ​ 117,020 Valuation allowance ​ (103,185) ​ (116,200) Net deferred tax assets ​ ​ 430 ​ ​ 820 Deferred tax liabilities: ​ ​ ​ ​ ​ ​ Financial liabilities ​ ​ 48 ​ 757 Property, plant and equipment ​ 382 ​ 63 Total deferred tax liability ​ ​ 430 ​ ​ 820 Deferred tax, net ​ $ — ​ $ — ​ The table below summarizes changes in the deferred tax valuation allowance: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands) 2018 2019 2020 Balance at beginning of year $ (80,087) $ (100,832) $ (103,185) Tax benefit ​ (7,301) ​ (2,353) ​ (13,015) Acquired tax attributes ​ ​ (13,444) ​ ​ — ​ ​ — Balance at end of year ​ $ (100,832) $ (103,185) $ (116,200) ​ The following table summarizes carryforwards of net operating losses as of December 31, 2020. ​ ​ ​ ​ ​ ​ ​ (in thousands) Amount Expiration Ireland ​ $ 251,775 Indefinite Austria ​ $ 248,563 Indefinite United States ​ $ 10,401 ​ Indefinite United States ​ $ 35,516 2033 ​ Due to uncertainty regarding the ability to realize the benefit of deferred tax assets primarily relating to net operating loss carryforwards and the fact that the Company is in a three year pretax cumulative loss position, a full valuation allowance has been established. On the basis of this evaluation, as of December 31, 2018, 2019 and 2020, the Company has recorded a valuation allowance of $100.8 million, $103.2 million and $116.2 million, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as our projections for growth. At December 31, 2020, the Company had no uncertain tax positions and did not expect any material increase or decrease in income tax expense related to examinations or changes in uncertain tax positions. At December 31, 2019, the Company received a tax assessment from the government in Austria resulting in a change of deferred tax assets. The assessment does not result in a cash settlement. The Company’s U.S. subsidiary, Nabriva Therapeutics US, Inc., is currently under examination for tax year 2018 with the Internal Revenue Service. The Company files income tax returns in Ireland. In addition, the Company’s foreign subsidiaries file separate income tax returns in Austria and the United States and state jurisdictions in which they are located. Tax years 2017 and forward remain open for examination for Ireland tax purposes and 2016 and forward remain open for examination for Austrian tax purposes and years 2016 and forward remain open for examination for United States tax purposes. The Company’s policy is to record interest and penalties related to tax matters in income tax expense.

Earnings (Loss) per Share

Earnings (Loss) per Share	12 Months Ended
	Dec. 31, 2020
Earnings (Loss) per Share
Earnings (Loss) per Share	14. Earnings (Loss) per Share Basic and diluted loss per share Basic and diluted loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of shares outstanding during the year. Diluted net loss per share is the same as basic net loss per share during the periods presented as the effects of the Company’s common stock equivalents are antidilutive and thus not included in the calculation. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands, except per share data) 2018 2019 2020 Net loss for the period ​ $ (114,780) ​ $ (82,764) ​ $ (69,484) Weighted average number of shares outstanding ​ 5,079,576 ​ 7,419,948 ​ 12,845,089 Basic and diluted loss per share ​ $ (22.60) ​ $ (11.15) ​ $ (5.41) ​ The following ordinary share equivalents were excluded from the calculations of diluted loss per share as their effect would be anti-dilutive: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 ​ 2018 2019 2020 Stock option awards 609,134 ​ 816,891 ​ 1,052,838 Restricted stock units 137,210 ​ 105,169 ​ 239,384 Warrants — ​ 1,379,310 ​ 5,438,842 ​

Acquisition of Zavante

Acquisition of Zavante	12 Months Ended
	Dec. 31, 2020
Acquisition of Zavante
Acquisition of Zavante	15. Acquisition of Zavante On July 24, 2018, the Company acquired Zavante. The acquisition was completed on July 24, 2018, or the Closing. In connection with the Closing, the Company issued 733,690 Company ordinary shares to former Zavante stockholders, which together with the 81,518 ordinary shares that were issued in July 2019 upon release of the Holdback Shares (as defined below) constitute approximately 19.9% of the Company ordinary shares outstanding as of immediately prior to the Closing, or the Upfront Shares. Pursuant to the Merger Agreement, former Zavante stockholders and other equity holders, in the aggregate and subject to the terms and conditions of the Merger Agreement, will also be entitled to receive from the Company up to $97.5 million in contingent consideration, of which $25.0 million would become payable upon the first approval of a NDA from the FDA for CONTEPO for any indication, or the Approval Milestone Payment, and an aggregate of up to $72.5 million would become payable upon the achievement of specified sales milestones, or theNet Sales Milestone Payments. At the Company’s Extraordinary General Meeting of Shareholders held in October 2018, the shareholders approved the issuance of the Company’s ordinary shares in settlement of potential milestone payment obligations that may become payable in the future to former Zavante stockholders, including the Approval Milestone Payment which will be settled in Company ordinary shares. The Company also now has the right to settle the Net Sales Milestone Payments in Company ordinary shares, except as otherwise provided in the Merger Agreement. In addition, upon the Closing, the Company assumed certain liabilities and obligations, including contractual liabilities and obligations. Prior to the Acquisition, Zavante was obligated to make milestone payments to the former stockholders of $3.0 million payable in cash upon marketing approval by the FDA with respect to any oral, intravenous or other form of fosfomycin, or the Zavante Products, and milestone payments of up to $26.0 million that may be settled in ordinary shares in the aggregate upon the occurrence of various specified levels of net sales with respect to the Zavante Products. In addition, Zavante is obligated to make annual royalty payments of a mid-single-digit percentage of net sales of Zavante Products, subject to adjustment based on net sales thresholds and with such percentage reduced to low single-digits if generic fosfomycin products account for half of the applicable market on a product-by-product and country-by-country basis. Zavante will also pay a mid-single-digit percentage of transaction revenue in connection with the consummation of the grant, sale, license or transfer of market exclusivity rights for a qualified infectious disease product (within the meaning of the 21st Century Cures Act, or the Cures Act) related to a Zavante Product. The Company accounted for the acquisition of Zavante as an asset acquisition as the arrangement did not meet the definition of a business pursuant to the guidance prescribed in ASC Topic 805, Business Combinations The Company expensed the acquired intellectual property as of the acquisition date as in- process research and development with no alternative future uses. The Company recorded an in-process research and development expense of $32.0 million which represents $26.9 million for the fair value of the Upfront Shares, $4.8 million of transaction costs and $0.2 million of net liabilities assumed. In addition, the Company assumed certain liabilities and obligations, including contractual liabilities and obligations, that were assumed by the Company upon closing of the acquisition. See “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Acquisition of Zavante” for further information regarding the agreements that were assumed by the Company.

Significant Arrangements and Li

Significant Arrangements and License Agreements	12 Months Ended
	Dec. 31, 2020
Significant Arrangements and License Agreements
Significant Arrangements and License Agreements	16. Significant Arrangements and License Agreements Sinovant License Agreement In March 2018, the Company entered into the Sinovant License Agreement, with Sinovant Sciences, Ltd., or Sinovant, an affiliate of Roivant Sciences, Ltd., to develop and commercialize lefamulin in the greater China region. As part of the Sinovant License Agreement, Nabriva Therapeutics Ireland DAC and Nabriva Therapeutics GmbH, the Company’s wholly owned subsidiaries, granted Sinovant an exclusive license to develop and commercialize, and a non-exclusive license to manufacture, certain products containing lefamulin, or the Sinovant Licensed Products, in the People’s Republic of China, Hong Kong, Macau, and Taiwan, together the Territory. Under the Sinovant License Agreement, Sinovant and the Company’s subsidiaries have established a joint development committee, or the JDC, to review and oversee development and commercialization plans in the Territory. The Company received a non-refundable $5.0 million upfront payment pursuant to the terms of the Sinovant License Agreement and will be eligible for up to an additional $91.5 million in milestone payments upon the achievement of certain regulatory and commercial milestone events related to lefamulin for CABP, plus an additional $4.0 million in milestone payments if any Sinovant Licensed Product receives a second or any subsequent regulatory approval in the People’s Republic of China. The first milestone was a $1.5 million payment for the submission of a clinical trial application, or CTA, by Sinovant to the Chinese Food and Drug Administration, which was received in the first quarter of 2019. Additionally, in connection with the FDA approval for lefamulin the Company received a $5.0 million milestone payment in the third quarter of 2019. The remaining milestone payments of $86.5 million are tied to additional regulatory approvals and annual sales targets. The Company will also be eligible to receive low double-digit royalties on sales, if any, of Sinovant Licensed Products in the Territory. In December 2020, the Company announced the restructuring of its license agreement with Sinovant Sciences for XENLETA in the greater China region. The restructured agreement provides for additional manufacturing collaboration and regulatory support to be provided to Sinovant by the Company that is expected to help expedite the delivery of XENLETA to patients in greater China. The restructured agreement also accelerates a portion of the $5.0 million milestone payment to the Company that was previously payable upon regulatory approval of XENLETA in China, including a non-refundable upfront payment of $1.0 million which was received in the fourth quarter of 2020. The Company will recognize the $1.0 million payment received as collaboration revenue in the consolidated statements of operations over the estimated period the manufacturing collaboration and regulatory support will be provided to Sinovant. The future regulatory and commercial milestone payments will be recorded during the period the milestones become probable of achievement. Except for the manufacturing collaboration and regulatory support discussed above, Sinovant will be solely responsible for all costs related to developing, obtaining regulatory approval of and commercializing Sinovant Licensed Products in the Territory and is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize Sinovant Licensed Products in the Territory. The Company is obligated to use commercially reasonable efforts to supply, pursuant to supply agreements to be negotiated by the parties, to Sinovant a sufficient supply of lefamulin for Sinovant to manufacture finished drug products for development and commercialization of the Sinovant Licensed Products in the Territory. Unless earlier terminated, the Sinovant License Agreement will expire upon the expiration of the last royalty term for the last Sinovant Licensed Product in the Territory, which the Company expects will occur in 2033. Following the expiration of the last royalty term, the license granted to Sinovant will become non-exclusive, fully-paid, royalty-free and irrevocable. The Sinovant License Agreement may be terminated in its entirety by Sinovant upon 180 days’ prior written notice at any time. Either party may, subject to specified cure periods, terminate the Sinovant License Agreement in the event of the other party’s uncured material breach. Either party may also terminate the Sinovant License Agreement under specified circumstances relating to the other party’s insolvency. The Company has the right to terminate the Sinovant License Agreement immediately if Sinovant does not reach certain development milestones by certain specified dates (subject to specified cure periods). The Sinovant License Agreement contemplates that the Company will enter into ancillary agreements with Sinovant, including clinical and commercial supply agreements and a pharmacovigilance agreement. Sunovion License Agreement In March 2019, the Company entered into the Sunovion License Agreement with Sunovion. As part of the Sunovion License Agreement, Nabriva Therapeutics Ireland DAC, the Company’s wholly owned subsidiary, granted Sunovion an exclusive license under certain patent rights, trademark rights and know-how to commercialize the Licensed Products in Canada in all uses in humans in community-acquired bacterial pneumonia and in any other indication for which the Licensed Products have received regulatory approval in Canada. Under the Sunovion License Agreement, Sunovion and DAC will establish a joint development committee (the “Sunovion JDC”), to review and oversee regulatory approval and commercialization plans in the Territory. Sunovion will be solely responsible for all costs related to obtaining regulatory approval of and commercializing Licensed Products in the Territory and is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize Licensed Product in the Territory. On November 7, 2019, the Company, through Sunovion, submitted a NDS. Health Canada determined there was a screening deficiency in December 2019 and a response from the Company/Sunovion was provided on December 18, 2019 and acknowledged by Health Canada on January 13, 2020. The NDS approval occurred on July 10, 2020. The Company has identified two performance obligations at inception: (1) the delivery of the exclusive license to Sunovion, which the Company has determined is a distinct license of functional intellectual property that Sunovion has obtained control of; and, (2) the participation in the Sunovion JDC. The $1.0 million non-refundable upfront payment was allocated entirely to the delivery of the license as the Sunovion JDC deliverable was deemed to be de minimis. With the NDS approval that occurred on July 10, 2020, the Company has received a regulatory milestone payment of $0.5 million . Any future regulatory and commercial milestone payments under the Sunovion License Agreement will be recorded during the period the milestones become probable of achievement. Sales Promotion and Distribution Agreement with Merck & Co. On July 15, 2020, the Company entered into a Sales Promotion and Distribution Agreement, or the Distribution Agreement, with MSD International GmbH, or MSD, and Merck Sharp & Dohme Corp., or Supplier, each a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Under the Distribution Agreement, upon satisfaction of certain specified conditions, MSD appointed the Company as its sole and exclusive distributor of certain products containing tedizolid phosphate as the active ingredient (marketed and sold by Supplier and MSD prior to the effective date of the Distribution Agreement under the trademark SIVEXTRO®) for injection, intravenous use and oral use, or the Products, in final packaged form labeled with the Company’s National Drug Code numbers in the United States and its territories, or the Territory. The Company expects to begin selling and reporting product revenue of its own brand of SIVEXTRO early in the second quarter of 2021. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible Gram-positive microorganisms. Under the Distribution Agreement and subject to the fulfillment of certain conditions, including the Company having engaged sufficient sales representatives, restrictions relating to travel and physician office access in the Territory due to COVID-19 having continued to decrease in a sufficient portion of the Territory so as not to hinder the successful detailing of SIVEXTRO, the Company is granted the right by MSD initially to promote the Products in the Territory and, upon satisfaction of additional conditions, including an increase in sales representatives, the right to exclusively distribute the Products in the Territory, including the sole right and responsibility to fill orders with respect to the Products in the Territory. Subject to applicable law, the Company is entitled to determine the final selling prices of the Products charged by the Company to its customers at its sole discretion, subject to an overall annual limit on price increases, and will be solely responsible for sales contracting and all market access activities, including bidding, hospital listing and reimbursement. The Company is responsible for all costs related to the promotion, sale and distribution of the Products by the Company, as well as all costs required to meet the Company’s staffing obligations under the Distribution Agreement. The Company is obligated to use commercially reasonable efforts to promote and distribute the Products and to maximize the sales of the Products throughout the Territory. The Company has agreed to employ a sales force or retain the services of a contract sales organization to fulfill its obligations under the Distribution Agreement. In September 2020, the Company began a small and focused sales effort, by utilizing 15 sales representatives in a virtual and in-person community-based sales effort with Amplity Health. The Company expanded this effort to 60 sales representatives in November 2020 and the Company may expand it further in 2021. Named Patient Program Agreement with WE Pharma Ltd. On June 30, 2020 the Company announced that WE Pharma Ltd., or WEP Clinical, a specialist pharmaceutical services company, had signed an exclusive agreement with the Company to supply XENLETA on a named patient or expanded access basis in certain countries outside of the US, China and Canada. The Named Patient Program, or NPP, is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet available and have an unmet medical need. ​

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies
Commitments and Contingencies	17. Commitments and Contingencies Leases The Company leases office spaces in King of Prussia, Pennsylvania, San Diego, California, Dublin, Ireland and laboratory and office space in Vienna, Austria under agreements previously classified as operating leases. In October 2020, the Company provided a notice of termination of our lease of approximately 15,000 square feet of office space in King of Prussia, Pennsylvania. The Company is obligated to pay the rent in King of Prussia through April 2021. In February 2021, the Company signed a sublease for approximately 8,000 square feet of office space in Fort Washington, Pennsylvania which became effective on March 1, 2021 and continues through July 2023, subject to certain early termination terms. The lease agreement in San Diego, California expired on June 30, 2019 and was not renewed by the Company. In May 2019, the Company entered into a month-to-month sublease agreement for office space for two employees in San Diego, California. For the lease agreement in Vienna Austria, the Company can terminate the lease without the landlord’s consent and without paying a termination penalty by giving six months ’ notice to the landlord. The agreement provides for a monthly base fixed amount. The Company is in the process of determining the appropriate space needed in the building based on its needs. As a result, the Company may negotiate a new lease or evaluate additional or alternate spaces. As such, the Company has classified the agreement as a short-term lease. During the third quarter of 2019, the Company subleased certain space at its leased cost. In March 2019, the Company entered into a lease agreement for office space in Dublin, Ireland which has been extended in January 2021 and expires on September 30, 2022. The agreement can be automatically renewed by both parties equal to the current lease term but for no less than three months . The agreement provides for a monthly based fixed amount of 7,000 euros beginning on the commencement date which was in May 2019. In addition to the monthly base amounts under the lease agreements, the Company is required to pay its proportionate share of real estate taxes and operating expenses during the lease term for the King of Prussia lease. Lease expense was $1.4 million, $1.5 million and $1.4 million for the years ended December 31, 2018, 2019 and 2020, respectively. As of December 31, 2020, the lease term of the King of Prussia operating leases was 0.3 years and the discount rate was 9.8% . As of December 31, 2020, other information related to the operating leases were as follows: Operating Cash Flow Supplemental Information: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years ended December 31, (in thousands) 2019 ​ 2020 Cash paid for amounts included in the measurement of the operating lease liabilities ​ $ 515 ​ $ 507 Right-of-use assets obtained in exchange for operating lease obligations ​ $ 1,647 ​ $ 226 ​ The following table sets forth by year the required future payments of operating lease liabilities: ​ ​ ​ ​ ​ ​ (in thousands) December 31, 2020 ​ 2021 ​ $ 171 ​ 2022 ​ — ​ 2023 ​ — ​ Total lease payments ​ 171 ​ Less imputed interest and amortization differences ​ ​ (3) ​ Present value of operating lease liabilities ​ 168 ​ ​ ​ Future minimum contractual obligations and commitments at December 31, 2020 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ending December 31, (in thousands) Total 2021 2022 2023 2024 2025 Thereafter Operating lease obligations ​ $ 743 ​ $ 743 ​ $ — ​ $ — ​ $ — ​ $ — ​ $ — Other contractual commitments ​ 58,166 ​ 14,059 ​ 12,569 ​ 12,838 ​ 9,350 ​ 9,350 ​ — Total ​ $ 58,909 ​ $ 14,802 ​ $ 12,569 ​ $ 12,838 ​ $ 9,350 ​ $ 9,350 ​ $ — ​ In addition to the agreements described above, the Company has other contractual commitments related primarily to contracts entered into with contract manufacturing organizations and contract research organizations in connection with the commercial manufacturing of XENLETA and other research and development activities. The estimated payments to the service providers included in the table above are based on the achievement of milestones included within the agreements. Also, some of these contracts are subject to early termination clauses exercisable at the discretion of the Company. Legal Proceedings On May 8, 2019, a putative class action lawsuit was filed against the Company and its Chief Executive Officer in the United States District Court for the Southern District of New York, captioned Larry Enriquez v. Nabriva Therapeutics PLC, and Ted Schroeder, No. 19-cv-04183. The complaint purported to be brought on behalf of shareholders who purchased the Company's securities between November 1, 2018 and April 30, 2019. The complaint generally alleged that the Company and its Chief Executive Officer violated Sections 10(b) and/or 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by making allegedly false and/or misleading statements and omitting to disclose material facts concerning the Company's submission of an NDA to the FDA for marketing approval of CONTEPO for the treatment of cUTI in the United States and the likelihood of such approval. The complaint sought unspecified damages, attorneys' fees, and other costs. On May 22, 2019, a second putative class action lawsuit was filed against the Company and its Chief Executive Officer in the United States District Court for the Southern District of New York, captioned Anthony Manna v. Nabriva Therapeutics PLC, and Ted Schroeder, No. 19-cv-04713. The complaint purported to be brought on behalf of shareholders who purchased the Company's securities between November 1, 2018 and April 30, 2019. The allegations made in the Manna complaint were similar to those made in the Enriquez complaint, and the Manna complaint sought similar relief. On May 24, 2019, these two lawsuits were consolidated by the court. The court appointed a lead plaintiff and approved plaintiff's selection of lead counsel on July 22, 2019. On September 23, 2019, plaintiff filed an amended complaint, adding the Company's Chief Financial Officer and Chief Medical Officer as defendants; the amended complaint purports to be brought on behalf of shareholders who purchased the Company's securities between January 4, 2019 through April 30, 2019, and otherwise includes allegations similar to those made in the original complaints and seeks similar relief. The Company's pre-motion letter to dismiss the amended complaint was due to plaintiff on October 21, 2019, and plaintiff responded to the Company via a letter on November 4, 2019. On November 18, 2019, the Company filed a pre-motion letter to dismiss with the Court, seeking leave to move to dismiss and setting forth why a motion to dismiss is warranted. On April 28, 2020, the Court dismissed the amended complaint without prejudice and granted plaintiff twenty days to show cause why the lawsuit should not be dismissed with prejudice. On May 8, 2020, the Court granted plaintiff a 21-day extension to show cause. On June 8, 2020, plaintiff filed a letter application to the court seeking leave to file a proposed second amended complaint, and on June 23, 2020, the court directed plaintiff to file the proposed second amended complaint. Plaintiff did so on June 24, 2020. The Company filed an answer to the second amended complaint on July 8, 2020. On October 21, 2020, the parties mediated this case and reached a settlement. On January 28, 2021, the court preliminarily approved the settlement, subject to further consideration at the final approval hearing, which is scheduled to be held on May 14, 2021. The settlement will be covered in full by our directors’ and officers’ insurance. The Company has no other contingent liabilities in respect of legal claims arising in the ordinary course of business. ​

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events
Subsequent Events	18. Subsequent Events On March 1, 2021, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to issue and sell in a registered direct offering (1) an aggregate of 9,761,010 ordinary shares, $0.01 nominal value per share, and accompanying warrants to purchase up to an aggregate of 4,880,505 ordinary shares and (2) pre-funded warrants to purchase up to an aggregate of 600,000 ordinary shares and accompanying ordinary share warrants to purchase up to an aggregate of 300,000 ordinary shares. Each share was issued and sold together with an accompanying ordinary share warrant at a combined price of $2.4525, and each pre-funded warrant was issued and sold together with an accompanying ordinary share warrant at a combined price of $2.4425. The proceeds to the Company from the offering were $25.4 million gross and $23.4 million net after deducting the placement agent’s fees and other estimated offering expenses. Each pre-funded warrant had an exercise price per ordinary share equal to $0.01 and each pre-funded warrant was exercised in full on the issuance date. Each ordinary share warrant has an exercise price per ordinary share equal to $2.39, was exercisable on the date of issuance and will expire on the five-year anniversary of the date of issuance.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Summary of Significant Accounting Policies
Basis of Preparation	Basis of Preparation The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or US GAAP, and US Securities and Exchange Commission, or SEC, regulations for annual reporting. The consolidated financial statements include the accounts of Nabriva Therapeutics plc and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Reverse Stock Split	Reverse Stock Split On December 2, 2020, the Company filed an Amended and Restated Memorandum and Articles of Association of the Company with the Irish Companies Registration Office and effected, a one-for-ten reverse stock split (the “Reverse Stock Split”) of the Company’s ordinary shares. As a result of the Reverse Stock Split, every ten ordinary shares in the authorized and unissued and authorized and issued share capital of the Company were consolidated into one ordinary share. No fractional shares were issued in connection with the Reverse Stock Split. Shareholders who would otherwise be entitled to a fractional ordinary share were instead entitled to receive a proportional cash payment. All ordinary share, per share and related information presented in the consolidated financial statements and notes has been retroactively adjusted to reflect the Reverse Stock Split.
Functional Currency Transactions and Balances	Functional Currency Transactions and Balances In preparing the consolidated financial statements, transactions in currencies other than the U.S. dollar are recognized at the exchange rates prevailing at the dates of the transactions. Foreign currency exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statements of operations.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents.
Restricted Cash	Restricted Cash ​ The Company classifies funds contributed by its employees to its Employee Stock Purchase Plan (See Note 11) as restricted in nature since these amounts can only be utilized to purchase Company stock at the end of each six month offering period. Prior to the conclusion of the offering period, employees can request reimbursement of the funds they previously contributed and if they leave the Company prior to the end of the offering period the funds are returned to the employee.
Short-term Investments	Short-term Investments The Company has designated its investments in securities as available-for-sale securities and measures these securities at their respective fair values. Investments that mature in one year or less are classified as short-term available-for-sale securities. Investments that are not considered available for use in current operations are classified as long-term available-for-sale securities. Changes in the fair value of available-for-sale investments are recognized in other comprehensive income (loss).
Inventory	Inventory ​ Inventory is stated at the lower of cost or net realizable value. Inventory is valued on a first-in, first-out basis and consists primarily of material costs, third-party manufacturing costs, and related transportation costs along the Company's supply chain. The Company capitalizes inventory upon regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are recorded as research and development expense. Costs of drug product to be consumed in any current or future clinical trials will continue to be recognized as research and development expense and costs of sample inventory is recorded as selling, general and administrative expense. The Company reviews inventories for realization on a quarterly basis and would record provisions for estimated excess, slow-moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value when necessary. For the year ended December 31, 2020, the Company recorded a $0.7 million non-cash reserve for excess and obsolete inventory due to the uncertainty of commercial activities underlying XENLETA product sales. ​ The components of our inventory at December 31, 2019 and 2020 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands) ​ 2019 ​ ​ 2020 Raw materials $ — ​ $ 952 Work in process 498 ​ 4,608 Finished goods 184 ​ 263 Total Inventory $ 682 ​ $ 5,823 ​
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are as follows: 3 5 3
Intangible Assets and Other Long-lived Assets	Intangible Assets and Other Long-lived Assets Intangible assets, such as acquired computer software licenses, are capitalized on the basis of the costs incurred to acquire the software and bring it into use. These costs are amortized on a straight-line basis over their estimated useful lives ( 3 Long-lived assets are assessed for potential impairment when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. An impairment loss would be recognized when undiscounted cash flows expected to be generated by an asset, is less than its carrying amount. The impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value and recognized in these financial statements.
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating segment, which is the commercialization and development of novel anti-infective agents to treat serious and life-threatening infections.
Revenue Recognition	Revenue Recognition Revenue from Contracts with Customers Net Product Revenue Beginning in September 2019, the Company began selling its XENLETA product principally to a limited number of specialty distributors in the United States. The distributors place orders with the Company for sufficient quantities of its products to maintain an appropriate level of inventory based on its customers’ anticipated purchase volumes and demand. The Company recognizes revenue once it has transferred physical possession of the goods and the distributor obtains legal title to the product. Payment terms between Nabriva and its customers are generally approximately 60 days from the invoice date. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of its product. The transaction price that the Company recognizes as revenue reflects the amount it expects to be entitled to in connection with the sale and transfer of control of product to its customers. At the time that the Company’s customers take control of the product, which is when the Company’s performance obligation under the sales contracts is complete, the Company records product revenues net of applicable reserves for various types of variable consideration. The types of variable consideration are as follows: ● Fees-for-service ● Product returns ● Chargebacks and rebates ● Government rebates ● Commercial payer and other rebates ● Group Purchasing Organizations, or GPO, administration fees ● Voluntary patient assistance programs In determining the amounts of certain allowances and accruals, the Company must make significant judgments and estimates. For example, in determining these amounts, the Company estimates prescription demand from the specialty pharmacies, hospital demand, buying patterns by hospitals, hospital systems and/or group purchasing organizations and the levels of inventory held by specialty distributors and customers. The Company also analyzes third party end usage product consumption patterns to gauge demand for its products. Making these determinations involves analyzing third party industry data to determine whether trends in historical channel distribution patterns will predict future product sales. The Company receives data periodically from its specialty distributors and customers on inventory levels and historical channel sales mix, and the Company considers this data when determining the amount of the allowances and accruals for variable consideration, however given the recent launch of its XENLETA product this data is limited. In assessing the amount of net revenue to record, the Company considers both the likelihood and the magnitude of the revenue reversal. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. The specific considerations the Company uses in estimating these amounts related to variable consideration associated with the Company’s products are as follows: Fees-for-service does not consider the fees separate from the distributors’ purchase of the product. The Company records its fee-for-service accruals based on distributors’ purchases and the applicable discount rate. Product returns history of XENLETA returns, the Company estimated returns based on industry data for comparable products in the market. As the Company distributes its product and establishes historical sales over a longer period of time (i.e., two to three years), the Company will be able to place more reliance on historical purchasing, demand and return patterns of its customers when evaluating its reserves for product returns. The Company’s XENLETA product has a thirty-six-month shelf life. their customers demand, product returns could increase in excess of what the Company has currently reserved which would result in a reduction to net revenues in future periods. ​ At the end of each reporting period for any of its products, the Company may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of product currently being shipped, price changes of competitive products and introductions of generic products. Chargebacks and rebates – Although the Company primarily sells products to specialty distributors in the United States, the Company also enters into agreements with hospitals and retail pharmacies, either directly or through group purchasing organizations acting on behalf of their members, in connection with the purchase of product. Based on these agreements, certain of the Company’s customers have the right to receive a discounted price on product purchases. The Company typically provides a credit to its specialty distributors customers (i.e., chargeback), representing the difference between the customer’s acquisition list price and the discounted price. The calculation of the accrual for chargebacks and rebates is based on estimates of claims and their associated cost that the Company expects to receive associated with product sales that have been recognized as revenue but remain in the distribution channel as inventory at the end of each reporting period. Government rebates –The Company is subject to discount obligations primarily under state Medicaid and Medicare programs. The Company estimates its Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payer mix. These reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The calculation of the accrual for government rebates is based on estimates of claims and their associated cost that the Company expects to receive associated with product sales that have been recognized as revenue but remain in the distribution channel as inventory at the end of each reporting period. Commercial payer and other rebates – The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of XENLETA and contracted formulary status. The Company estimates these rebates and records reserves for such estimates in the same period the related revenue is recognized. Currently, the reserve for customer payer rebates considers future utilization based on third party studies of payer prescription data; the utilization is applied to product that remains in the distribution and retail pharmacy channel inventories at the end of each reporting period. The calculation of the accrual for commercial payer and other rebates is based on estimates of claims and their associated cost that the Company expects to receive associated with product sales that have been recognized as revenue but remain in the distribution channel as inventory at the end of each reporting period. GPO administration fees – The Company contracts with GPOs and pays administration fees related to contacting and membership management services provided. In assessing if the consideration paid to the GPO should be recorded as a reduction in the transaction price, the Company determines whether the payment is for a distinct good or service or a combination of both. Since GPO fees are not specifically identifiable, the Company does not consider the fees separate from the purchase of the product. Additionally, the GPO services generally cannot be provided by a third party. Because of these factors, the consideration paid is considered a reduction of revenue. Patient assistance At the end of each reporting period, the Company will adjust its variable consideration estimates for product returns, chargebacks, and rebates when the Company believes actual experience may differ from current estimates. The following table summarizes balances and activity of product revenue allowances and reserves: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2019 ​ 2020 Balance at January 1 ​ $ — ​ $ 534 Provision related to current period sales ​ 635 ​ 182 Adjustment related to prior period sales ​ — ​ 194 Credit or payments made during the period ​ (101) ​ (248) Balance at December 31 ​ $ 534 ​ $ 662 ​ Cost of Product Sales Cost of product sales primarily represents direct and indirect manufacturing costs of XENLETA. Prior to the FDA approval of XENLETA on August 19, 2019, the inventory costs for the product were expensed as research and development expenses since the approval was outside of the Company’s control and therefore not considered probable. As such, the majority of the expenses incurred for initial inventories of XENLETA has been previously expensed. For the year ended December 31, 2020 the cost of product sales includes a $0.7 million non-cash reserve for excess and obsolete inventory due to the uncertainty of commercial activities underlying XENLETA sales.
Research Premium and Grant Revenue	Research Premium and Grant Revenue Grant revenue comprises (a) the research premium from the Austrian government, (b) grants received from the Austrian Research Promotion Agency ( Österreichische Forschungsförderungsgesellschaft, or FFG The research premium the Company receives from the Austrian government is calculated at a specified percent of specified research and development cost base. The Company recognizes the research premium as long as it has incurred research and development expenses. All grants are non-refundable as long as the conditions of the grant are met. Nabriva is and has been in full compliance with the conditions of the grants and all related regulations.
Research and Development Expenses	Research and Development Expenses All research and development costs are expensed as incurred. Research and development costs included direct personnel and material costs, related overheads, depreciation of equipment used for research or development purposes; costs for clinical research; costs for the utilization of third parties’ patents for research and development purposes and other taxes related to research facilities.
Share-based Payments	Share-based Payments The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award in accordance with ASC 718, Compensation — Stock Compensation
Leases	Leases In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases the previous lease standard in its annual disclosures for the comparative periods. In addition, the new lease standard provides a number of optional practical expedients in transition. The Company elected the package of practical expedients. As such, the Company did not have to reassess whether expired or existing contracts are or contain a lease; and did not have to reassess the lease classifications or reassess the initial direct costs associated with expired or existing leases. The new lease standard also provides practical expedients for an entity's ongoing accounting. The Company elected the short-term lease recognition exemption under which the Company will not recognize right of use, or ROUassets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases. The Company elected the practical expedient to not separate lease and non-lease components for certain classes of assets (office buildings). The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease ROU assets, other current liabilities, and operating lease liabilities on the Company’s consolidated balance sheet. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the remaining lease term. Since none of the Company’s lease agreements provide an implicit rate, the Company estimated an incremental borrowing rate over the lease term based on the information available at January 1, 2020 in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as operating costs and property taxes are expensed as incurred. On January 1, 2019, the Company recognized ROU assets and lease liabilities property, plant and equipment ROU liability December 31, 2020
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. In recognizing the benefit of tax positions, the Company has taken or expects to take, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company’s policy is to record interest and penalties related to tax matters in income tax expense.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Adopted as of the current period: Customer’s Accounting for Implementation Cost Incurred in a Cloud Computing Arrangement That Is a Service Contract

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Summary of Significant Accounting Policies
Schedule of inventory	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands) ​ 2019 ​ ​ 2020 Raw materials $ — ​ $ 952 Work in process 498 ​ 4,608 Finished goods 184 ​ 263 Total Inventory $ 682 ​ $ 5,823
Schedule of summary of balances and activity in each of the product revenue allowance and reserve	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2019 ​ 2020 Balance at January 1 ​ $ — ​ $ 534 Provision related to current period sales ​ 635 ​ 182 Adjustment related to prior period sales ​ — ​ 194 Credit or payments made during the period ​ (101) ​ (248) Balance at December 31 ​ $ 534 ​ $ 662

Short-term investments (Tables)

Short-term investments (Tables)	12 Months Ended
	Dec. 31, 2020
Short-term investments
Schedule of short-term investments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Term deposits ​ $ 16 ​ $ — ​ $ — ​ $ 16 Total ​ $ 16 ​ $ — ​ $ — ​ $ 16 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2019 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Term deposits ​ ​ 175 ​ ​ — ​ ​ — ​ ​ 175 Total ​ $ 175 ​ $ — ​ $ — ​ $ 175 ​

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Measurement
Schedule of the financial instruments measured at fair value and classified by level according to the fair value measurement hierarchy	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Total December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalent: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market fund ​ $ 8,050 ​ $ — ​ $ — $ 8,050 Short term investments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Term deposits ​ ​ 16 ​ ​ — ​ ​ — ​ 16 Total Assets ​ $ 8,066 ​ $ — ​ $ — $ 8,066 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Total December 31, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalent: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market fund ​ $ 15,050 ​ $ — ​ $ — $ 15,050 Short term investments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Term deposits ​ 175 ​ — ​ — ​ 175 Total Assets ​ $ 15,225 ​ $ — ​ $ — $ 15,225 ​

Accounts receivable, net and _2

Accounts receivable, net and other receivables (Tables)	12 Months Ended
	Dec. 31, 2020
Accounts receivable, net and other receivables
Schedule of other current receivables	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31 (in thousands) 2019 2020 Receivables from collaborative arrangments ​ $ — ​ $ 2,426 Research premium ​ ​ 1,530 ​ ​ 1,308 Other receivables ​ 1,214 ​ 175 Total accounts receivable, net and other receivables ​ $ 2,744 ​ $ 3,909

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment
Schedule of property, plant and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31 (in thousands) 2019 2020 IT equipment ​ $ 1,060 ​ $ 1,077 Laboratory equipment ​ 3,375 ​ 3,392 ROU asset ​ ​ 1,647 ​ ​ 226 Other equipment ​ 165 ​ 204 ​ ​ ​ 6,247 ​ ​ 4,899 Less: Accumulated depreciation ​ ​ (3,773) ​ ​ (4,131) Property, plant and equipment, net ​ $ 2,474 ​ $ 768

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Accrued Expenses and Other Current Liabilities
Schedule of accrued expenses and other current liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands) 2019 2020 Research and development related costs ​ $ 1,347 ​ $ 1,055 Payroll and related costs ​ 6,327 ​ 4,049 Accounting, tax and audit services ​ 420 ​ 470 Manufacturing and inventory ​ ​ 639 ​ ​ 4,779 Accrued gross to net ​ ​ 534 ​ ​ 662 Other ​ 2,699 ​ 1,829 Total other current liabilities ​ $ 11,966 ​ $ 12,844

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2020
Debt
Schedule of long-term debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands) 2019 2020 Term loan payable $ 35,000 $ 5,000 End of term fee ​ ​ 443 ​ ​ 2,048 Unamortized debt issuance costs ​ (1,742) ​ (206) Carrying value of term loan ​ ​ 33,701 ​ ​ 6,842 Other long-term debt ​ ​ 801 ​ ​ 885 Less: Amounts due within one year ​ ​ — ​ ​ (2,041) Total long-term debt $ 34,502 $ 5,686
Schedule of maturities of long-term debt	​ ​ ​ ​ ​ (in thousands) ​ ​ ​ 2021 $ 2,041 2022 ​ 2,493 2023 ​ ​ 4,084

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2020
Revenue
Summary of revenue by type	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands) 2018 2019 2020 Product revenue, net ​ $ — ​ $ 1,538 ​ $ 108 Collaboration revenues ​ ​ 6,500 ​ ​ 6,210 ​ ​ 2,756 Research premium ​ ​ 2,594 ​ ​ 1,311 ​ ​ 1,227 Government grants ​ 562 ​ 422 ​ 936 Total ​ $ 9,656 ​ $ 9,481 ​ $ 5,027
Summary of gross-to-net ("GTN") adjustments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, (in thousands) 2019 2020 Product revenue, gross $ 2,173 $ 484 GTN accruals ​ ​ ​ ​ ​ ​ Chargebacks and cash discounts ​ 48 ​ 16 Medicaid and Medicare rebates ​ ​ 223 ​ ​ 52 Other returns, rebates, discounts and adjustments ​ ​ 364 ​ ​ 115 Total GTN accruals ​ ​ (635) ​ ​ (183) Product revenue ​ ​ 1,538 ​ ​ 301 Adjustments to prior period accruals ​ ​ ​ ​ ​ ​ Returns reserve (1) ​ ​ — ​ ​ (421) GTN accrual adjustments ​ ​ — ​ ​ 228 Product revenue, net $ 1,538 $ 108

Share-Based Payments (Tables)

Share-Based Payments (Tables)	12 Months Ended
	Dec. 31, 2020
Share-Based Payments
Schedule of allocation of share-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands) 2018 2019 2020 Research and development ​ $ 1,406 ​ $ 2,138 ​ $ 1,280 Selling, general and administrative ​ 3,748 ​ 7,610 ​ 3,939 Total ​ $ 5,154 ​ $ 9,748 ​ $ 5,219 ​
Stock Option Plan 2015
Share-Based Payments
Summary of information regarding stock option awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2018 ​ 2019 ​ 2020 ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ ​ ​ ​ exercise ​ ​ ​ exercise ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in ​ ​ ​ price in ​ ​ ​ price in ​ intrinsic Stock Option Plan 2015 ​ Options $ per share ​ Options $ per share Options $ per share value Outstanding as of January 1, ​ 304,489 ​ 83.54 ​ 284,291 83.41 ​ 229,060 ​ 83.27 ​ Granted ​ — ​ — ​ — — ​ — ​ — ​ ​ Exercised ​ — ​ — ​ — — ​ — ​ — ​ ​ Forfeited ​ (20,198) ​ 84.07 ​ (55,231) 84.01 ​ (26,686) 87.46 ​ ​ Outstanding as of December 31, ​ 284,291 83.41 ​ 229,060 83.27 202,374 ​ 82.71 ​ $ — Vested and exercisable as of December 31, ​ 184,459 80.97 ​ 198,491 81.98 198,574 82.51 ​ $ —
2017 Share Incentive Plan
Share-Based Payments
Summary of information regarding stock option awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2018 ​ 2019 ​ 2020 ​ ​ ​ ​ ​ Weighted ​ ​ Weighted ​ ​ Weighted ​ ​ ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ ​ ​ exercise ​ ​ ​ exercise ​ ​ ​ exercise ​ ​ Aggregate ​ ​ ​ price in $ ​ ​ ​ price in $ ​ ​ ​ price in $ ​ ​ intrinsic 2017 Plan Options per share ​ Options per share Options per share ​ value Outstanding as of January 1, 29,410 ​ 69.17 ​ 239,842 ​ 54.14 442,266 ​ 35.48 Granted 219,922 ​ 52.71 ​ 246,330 ​ 19.51 129,050 ​ 13.50 Exercised — ​ — ​ — ​ — — ​ — Forfeited (9,490) ​ 67.52 ​ (43,906) ​ 47.87 (128,472) ​ 29.39 ​ ​ Outstanding as of December 31, 239,842 ​ 54.14 ​ 442,266 ​ 35.48 442,844 ​ 30.89 ​ $ — Vested and exercisable as of December 31, 11,928 ​ 68.77 ​ 112,028 ​ 55.33 228,731 ​ 39.02 ​ $ — ​
Summary of assumptions used for valuation of options	​ ​ ​ ​ ​ ​ ​ Input parameters 2018 2019 2020 Range of expected volatility 59.8% - 61.4% 61.4% - 63.1% 63.8% - 64.0% Expected term of options (in years) 6.1 6.0 6.1 Range of risk-free interest rate 2.6% - 3.0% 1.9% - 2.6% 0.8% - 1.5% Dividend yield — – —
Summary of information regarding restricted stock awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2019 ​ 2020 ​ ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ average fair ​ ​ ​ average fair 2017 Plan RSUs ​ value in $ per share ​ RSUs ​ value in $ per share Outstanding as of January 1, 122,210 ​ 33.10 ​ 90,169 ​ 27.37 Granted 47,900 ​ 19.00 ​ 155,730 ​ 13.50 Vested and issued (65,758) ​ 31.80 ​ (51,671) ​ 30.95 Forfeited (14,183) ​ 27.87 ​ (42,959) ​ 17.23 Outstanding as of December 31, 90,169 ​ 27.37 ​ 151,269 ​ 14.56
2019 Inducement Plan
Share-Based Payments
Summary of information regarding stock option awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2019 ​ 2020 ​ ​ ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ ​ ​ exercise ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in $ ​ ​ ​ price in $ ​ intrinsic 2019 Inducement Plan Options per share Options per share value Outstanding as of January 1 — ​ — 60,565 ​ 21.45 Granted 70,315 ​ 22.20 18,200 ​ 13.50 Exercised — — — ​ — Forfeited (9,750) ​ 26.92 (52,950) ​ 19.59 Outstanding as of December 31 60,565 ​ 21.45 25,815 ​ 19.04 ​ — Vested and exercisable as of December 31 — ​ — 4,396 ​ 26.96 ​ —
Summary of assumptions used for valuation of options	​ ​ ​ ​ ​ ​ Input parameters 2019 ​ 2020 Range of expected volatility 59.8% - 61.4% ​ 63.7% - 64.0% Expected term of options (in years) 6.1 ​ 6.1 Range of risk-free interest rate 2.55% - 3.03% ​ 0.96% - 1.37% Dividend yield – ​ –
Inducement Awards Outside of the 2019 Inducement Plan
Share-Based Payments
Summary of assumptions used for valuation of options	​ ​ ​ ​ ​ Input parameters ​ ​ Expected volatility 59.8 % Expected term of options (in years) 6.1 ​ Range of risk-free interest rate 2.9 % Dividend yield — ​ ​
2020 Share Incentive Plan
Share-Based Payments
Summary of information regarding stock option awards	​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in $ ​ intrinsic 2020 Plan Options per share value Outstanding as of January 1, — ​ — Granted 317,805 ​ 10.24 Exercised — ​ — Forfeited (21,000) ​ 7.88 Outstanding as of December 31, 296,805 ​ 10.18 ​ — Vested and exercisable as of December 31, — ​ — ​ —
Summary of assumptions used for valuation of options	​ ​ ​ ​ Input parameters 2020 Expected volatility 73.0% - 74.4% Expected term of options (in years) 5.5 - 6.1 Risk-free interest rate 0.34% - 0.51% Dividend yield —

Income tax expense (Tables)

Income tax expense (Tables)	12 Months Ended
	Dec. 31, 2020
Income tax expense
Schedule of loss before income taxes attributable to domestic and international operations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 (in thousands) 2018 2019 2020 Domestic ​ $ (113,699) ​ $ (78,761) ​ $ (71,344) Foreign ​ (1,032) ​ (3,902) ​ 1,999 Loss before income taxes ​ $ (114,731) ​ $ (82,663) ​ $ (69,345) ​
Schedule of income tax expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 (in thousands) 2018 2019 2020 Current tax ​ ​ ​ ​ ​ ​ ​ ​ ​ Domestic ​ $ — ​ $ — ​ $ — Foreign ​ (49) ​ (101) ​ (139) Deferred tax ​ ​ ​ ​ ​ ​ ​ ​ ​ Domestic ​ — ​ — ​ — Foreign ​ — ​ — ​ — Total income tax expense ​ $ (49) ​ $ (101) ​ $ (139) ​
Schedule of effective income tax rate reconciliation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 ​ (% of pre-tax income) 2018 2019 2020 ​ Statutory income tax rate 12.5 % 12.5 % 12.5 % Non-deductible expenses (0.1) ​ (0.1) ​ — ​ Income not subject to tax 0.3 ​ 0.3 ​ 0.2 ​ Tax credits 0.1 ​ 0.4 ​ 0.6 ​ Foreign rate differential (3.1) ​ 0.6 ​ 3.0 ​ In-process research and development ​ (3.5) ​ — ​ — ​ Tax audit assessments — ​ (11.8) ​ — ​ Other ​ 0.2 ​ 0.8 ​ 2.3 ​ Valuation allowance (6.5) ​ (2.8) ​ (18.8) ​ Effective income tax rate (0.1) % (0.1) % (0.2) % ​
Summary of the components of deferred income tax balances	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands) 2019 2020 Deferred tax assets: ​ ​ ​ ​ Net operating loss carryforwards ​ $ 94,014 ​ $ 108,095 Tax loss on liquidation of subsidiary ​ ​ 5,024 ​ ​ 4,029 Equity compensation ​ 4,182 ​ 4,449 Non-deductible reserves ​ 395 ​ 447 Total deferred tax assets ​ ​ 103,615 ​ ​ 117,020 Valuation allowance ​ (103,185) ​ (116,200) Net deferred tax assets ​ ​ 430 ​ ​ 820 Deferred tax liabilities: ​ ​ ​ ​ ​ ​ Financial liabilities ​ ​ 48 ​ 757 Property, plant and equipment ​ 382 ​ 63 Total deferred tax liability ​ ​ 430 ​ ​ 820 Deferred tax, net ​ $ — ​ $ — ​
Summary of changes in the deferred tax valuation allowance	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands) 2018 2019 2020 Balance at beginning of year $ (80,087) $ (100,832) $ (103,185) Tax benefit ​ (7,301) ​ (2,353) ​ (13,015) Acquired tax attributes ​ ​ (13,444) ​ ​ — ​ ​ — Balance at end of year ​ $ (100,832) $ (103,185) $ (116,200) ​
Summary of carryforwards of net operating losses	​ ​ ​ ​ ​ ​ ​ (in thousands) Amount Expiration Ireland ​ $ 251,775 Indefinite Austria ​ $ 248,563 Indefinite United States ​ $ 10,401 ​ Indefinite United States ​ $ 35,516 2033

Earnings (Loss) per Share (Tabl

Earnings (Loss) per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings (Loss) per Share
Schedule of basic and diluted loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands, except per share data) 2018 2019 2020 Net loss for the period ​ $ (114,780) ​ $ (82,764) ​ $ (69,484) Weighted average number of shares outstanding ​ 5,079,576 ​ 7,419,948 ​ 12,845,089 Basic and diluted loss per share ​ $ (22.60) ​ $ (11.15) ​ $ (5.41) ​
Schedule of ordinary share equivalents excluded from the calculations of diluted loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31 ​ 2018 2019 2020 Stock option awards 609,134 ​ 816,891 ​ 1,052,838 Restricted stock units 137,210 ​ 105,169 ​ 239,384 Warrants — ​ 1,379,310 ​ 5,438,842

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies
Schedule of operating cash flow supplemental information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years ended December 31, (in thousands) 2019 ​ 2020 Cash paid for amounts included in the measurement of the operating lease liabilities ​ $ 515 ​ $ 507 Right-of-use assets obtained in exchange for operating lease obligations ​ $ 1,647 ​ $ 226
Schedule of future payments of operating lease liabilities, ASC 842	​ ​ ​ ​ ​ ​ (in thousands) December 31, 2020 ​ 2021 ​ $ 171 ​ 2022 ​ — ​ 2023 ​ — ​ Total lease payments ​ 171 ​ Less imputed interest and amortization differences ​ ​ (3) ​ Present value of operating lease liabilities ​ 168 ​
Schedule of future minimum contractual obligations and commitments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ending December 31, (in thousands) Total 2021 2022 2023 2024 2025 Thereafter Operating lease obligations ​ $ 743 ​ $ 743 ​ $ — ​ $ — ​ $ — ​ $ — ​ $ — Other contractual commitments ​ 58,166 ​ 14,059 ​ 12,569 ​ 12,838 ​ 9,350 ​ 9,350 ​ — Total ​ $ 58,909 ​ $ 14,802 ​ $ 12,569 ​ $ 12,838 ​ $ 9,350 ​ $ 9,350 ​ $ —

Organization and Business Act_2

Organization and Business Activities (Details) $ / shares in Units, $ in Thousands	Mar. 01, 2021$ / sharesshares	Mar. 11, 2020USD ($)	Jul. 31, 2018USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / sharesshares	Jan. 31, 2021USD ($)shares	Dec. 31, 2020USD ($)$ / sharesshares	Nov. 30, 2020employee	Sep. 30, 2020employee	May 31, 2020USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 25, 2019USD ($)
Liquidity
Cash, cash equivalents and short-term investments						$ 41,600				$ 41,600
Selling, general and administrative expenses										55,285	$ 62,485	$ 41,743
Number of sales representatives | employee							60	15
Proceeds from at-the-market facility										$ 7,520	$ 27,945	$ 24,219
Net proceeds from sale of stock									$ 35,200
Nominal value | $ / shares						$ 0.01				$ 0.01	$ 0.01
Public offering
Liquidity
Number of shares issued | shares						6,000,000				6,000,000
Shares Issued, Price Per Share | $ / shares						$ 2.50				$ 2.50
Proceeds from at-the-market facility						$ 15,000				$ 15,000
Net proceeds from sale of stock						$ 13,300				13,300
Public offering | Ordinary Shares
Liquidity
Number of shares issued | shares			1,818,181
Shares Issued, Price Per Share | $ / shares			$ 27
Proceeds from at-the-market facility			$ 50,000
Net proceeds from sale of stock			$ 46,300
Purchase agreement
Liquidity
Number of shares issued | shares									4,144,537
Proceeds from at-the-market facility									$ 38,000
Net proceeds from sale of stock									$ 35,200
Number of ordinary shares that can be purchased by warrant holders | shares									4,144,537
Share and warrant price | $ / shares									$ 9.1686
Jefferies LLC | At-the-market offering
Liquidity
Maximum aggregate gross proceeds under the sales agreement													$ 50,000	$ 50,000
Proceeds from at-the-market facility					$ 16,300					21,900
Net proceeds from sale of stock					$ 11,500					$ 20,400
Jefferies LLC | At-the-market offering | Ordinary Shares
Liquidity
Number of shares issued | shares					3,933,350					1,992,390
Jefferies LLC | Estimate | At-the-market offering
Liquidity
Number of shares issued | shares					3,933,350
Net proceeds from sale of stock					$ 11,500
Jefferies LLC | Estimate | At-the-market offering | Maximum
Liquidity
Proceeds from at-the-market facility					$ 16,300
Purchasers | Purchase agreement
Liquidity
Number of shares issued | shares									4,144,537		1,379,310
Proceeds from at-the-market facility											$ 20,000
Net proceeds from sale of stock											$ 18,300
Number of ordinary shares that can be purchased by warrant holders | shares									4,144,537		1
Share and warrant price | $ / shares									$ 9.1686		$ 14.50
Exercise price | $ / shares						$ 7.92				$ 7.92
Term						2 years				2 years
Warrants outstanding | shares						4,059,532				4,059,532
Loan Agreement | Term loan
Liquidity
Repayment of debt		$ 30,000								$ 30,000
Aggregate principal amount of debt outstanding		$ 35,000
Subsequent Event | Purchasers | Purchase agreement
Liquidity
Number of shares issued | shares	9,761,010			9,761,010
Net proceeds from sale of stock				$ 23,400
Proceeds from Issuance or Sale of Equity				$ 25,400
Number of ordinary shares that can be purchased by warrant holders | shares	4,880,505			4,880,505
Term				5 years
Subsequent Event | Ordinary Share Warrants | Purchasers | Purchase agreement
Liquidity
Number of ordinary shares that can be purchased by warrant holders | shares				300,000
Nominal value | $ / shares	$ 0.01			$ 0.01
Share and warrant price | $ / shares				2.4525
Exercise price | $ / shares				$ 2.39
Subsequent Event | Pre-Funded Warrants | Purchasers | Purchase agreement
Liquidity
Number of ordinary shares that can be purchased by warrant holders | shares				600,000
Share and warrant price | $ / shares				$ 2.4425
Exercise price | $ / shares				$ 0.01

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)
Summary of Significant Accounting Policies
Raw materials	$ 952
Work in process	4,608	$ 498
Finished goods	263	184
Total Inventory	$ 5,823	$ 682
Conversion ratio of common stock to ordinary shares	1
Fractional shares issued | shares	0
Obsolete inventory non-cash reserve	$ 700

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2020
IT equipment | Minimum
Property, Plant and Equipment
Estimated useful life of property, plant and equipment	3 years
IT equipment | Maximum
Property, Plant and Equipment
Estimated useful life of property, plant and equipment	5 years
Laboratory equipment | Minimum
Property, Plant and Equipment
Estimated useful life of property, plant and equipment	5 years
Laboratory equipment | Maximum
Property, Plant and Equipment
Estimated useful life of property, plant and equipment	10 years
Other equipment | Minimum
Property, Plant and Equipment
Estimated useful life of property, plant and equipment	3 years
Other equipment | Maximum
Property, Plant and Equipment
Estimated useful life of property, plant and equipment	10 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Intangible Assets and Other Long-lived Assets and Segment Information (Details)	12 Months Ended
	Dec. 31, 2020segment
Intangible assets
Number of operating segments	1
Minimum
Intangible assets
Estimated useful life of intangible assets	3 years
Maximum
Intangible assets
Estimated useful life of intangible assets	10 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Product Revenue Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Movement In Product Revenue Allowance And Reserve [Roll Forward]
Balance at January 1	$ 534
Provision related to current period sales	182	$ 635
Adjustment related to prior period sales	194
Credit or payments made during the period	(248)	(101)
Balance at December 31	$ 662	$ 534

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Jan. 01, 2019
Leases
Operating lease liabilities	$ 168
Operating lease liability, Statement of Financial Position	us-gaap:OtherLiabilitiesNoncurrent
King of Prussia
Leases
Operating Lease, Increase (Decrease) In Right Of Use Asset	$ 1,100
Operating Lease, Increase (Decrease) In Lease Liability	$ 1,100
ASU 2016-02
Leases
Election of practical expedients package	true
ASU 2016-02 | Adjustment
Leases
ROU assets		$ 2,000
Operating lease, ROU assets, Statement of Financial Position		us-gaap:PropertyPlantAndEquipmentNet
Operating lease liabilities		$ 2,000
Operating lease liability, Statement of Financial Position		us-gaap:OtherLiabilitiesNoncurrent
Estimated incremental borrowing rate		9.80%

Short-term investments (Details

Short-term investments (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Short-term investments
Amortized Cost	$ 16	$ 175
Fair Value	16	175
Term deposits
Short-term investments
Amortized Cost	16	175
Fair Value	$ 16	$ 175

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Short-term investments:
Transfer of assets from Level 1 to 2	$ 0	$ 0
Transfer of assets from Level 2 to 1	0	0
Transfer of liabilities from Level 1 to 2	0	0
Transfer of liabilities from Level 2 to 1	0	0
Recurring
Cash equivalent:
Money market funds	8,050	15,050
Short-term investments:
Term deposits	16	175
Total Assets	8,066	15,225
Level 1 | Recurring
Cash equivalent:
Money market funds	8,050	15,050
Short-term investments:
Term deposits	16	175
Total Assets	$ 8,066	$ 15,225

Accounts receivable, net and _3

Accounts receivable, net and other receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Other receivables
Receivables From Collaborative Arrangements	$ 2,426
Research premium	1,308	$ 1,530
Other receivables	175	1,214
Total accounts receivable, net and other receivables	$ 3,909	$ 2,744

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment
Property, plant and equipment, gross	$ 4,899	$ 6,247
Less: Accumulated depreciation	(4,131)	(3,773)
Property, plant and equipment, net	768	2,474
IT equipment
Property, Plant and Equipment
Property, plant and equipment, gross	1,077	1,060
Laboratory equipment
Property, Plant and Equipment
Property, plant and equipment, gross	3,392	3,375
ROU asset
Property, Plant and Equipment
Property, plant and equipment, gross	226	1,647
Other equipment
Property, Plant and Equipment
Property, plant and equipment, gross	$ 204	$ 165

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accrued expenses and other liabilities
Research and development related costs	$ 1,055	$ 1,347
Payroll and related costs	4,049	6,327
Accounting, tax and audit services	470	420
Manufacturing and inventory	4,779	639
Accrued gross to net	662	534
Other	1,829	2,699
Total other current liabilities	$ 12,844	$ 11,966

Debt - Summary (Details)

Debt - Summary (Details) - USD ($) $ in Thousands	Mar. 11, 2020	Feb. 29, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt
Minimum amount to be maintained in cash and cash equivalents	$ 3,000
Loan origination costs			$ 1,300
Initial fee paid to lender			700
Loss on extinguishment of debt			(2,757)
Term loan
Debt
End of term fee			$ 5,000	$ 35,000
Loan Agreement | Term loan
Debt
Maximum borrowing capacity					$ 75,000
Principal amount of advances outstanding	35,000
Interest rate (as a percent)			9.80%
Fee due at maturity, as a percentage of aggregate advances			6.95%
The amount in excess of which prepayments may be made			$ 5,000
Repayment of debt	$ 30,000		30,000
Percent of net product revenue sales target	70.00%	80.00%
Minimum liquidity requirement		$ 40,000
Maximum value of lender option to purchase equity securities			2,000
End of term loan charge payment	$ 2,100
End of term loan charge	$ 300,000	$ 600,000
Loss on extinguishment of debt			2,700
End of term fee			$ 5,000
Loan Agreement | Term loan | Prime rate
Debt
Variable rate basis			interest minus 5.50%
Variable interest rate margin (as a percent)			9.80%
Variable rate adjustment (as a percent)			5.50%
Loan Agreement | Term loan | Initial Advance
Debt
Principal amount of advances outstanding					25,000
Loan Agreement | Term loan | Tranche 7 Advance
Debt
Maximum borrowing capacity					$ 5,000
Additional tranches			$ 5,000
Loan Agreement | Term loan | Prepayment during the first 12 months following initial closing
Debt
Prepayment penalty as a percentage of the amount being repaid			3.00%
Loan Agreement | Term loan | Prepayment after the first 12 months following initial closing but before 24 months
Debt
Prepayment penalty as a percentage of the amount being repaid			2.00%
Loan Agreement | Term loan | Prepayment after the first 24 months following initial closing but before maturity
Debt
Prepayment penalty as a percentage of the amount being repaid			1.00%

Debt - Long-Term Debt (Details)

Debt - Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Long-term debt
Less: Amounts due within one year	$ (2,041)
Total long-term debt	5,686	$ 34,502
Maturities of long-term debt
2021	2,041
2022	2,493
2023	4,084
Term loan
Long-term debt
Term loan payable	5,000	35,000
End of term fee	2,048	443
Unamortized debt issuance costs	(206)	(1,742)
Total long-term debt	6,842	33,701
Other long-term debt
Long-term debt
Total long-term debt	$ 885	$ 801

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 31, 2018	Jan. 31, 2021	Dec. 31, 2020	May 31, 2020	Jun. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Jun. 25, 2019	Mar. 31, 2018
Stockholders' Equity
Gross proceeds from sale of stock						$ 7,520	$ 27,945	$ 24,219
Net proceeds from sale of stock				$ 35,200
Public offering
Stockholders' Equity
Number of shares issued			6,000,000			6,000,000
Shares issued, price per share			$ 2.50			$ 2.50
Gross proceeds from sale of stock			$ 15,000			$ 15,000
Net proceeds from sale of stock			$ 13,300			13,300
Public offering | Ordinary Shares
Stockholders' Equity
Number of shares issued	1,818,181
Shares issued, price per share	$ 27
Gross proceeds from sale of stock	$ 50,000
Net proceeds from sale of stock	$ 46,300
Purchase agreement
Stockholders' Equity
Number of shares issued				4,144,537
Number of ordinary shares that can be purchased by warrant holders				4,144,537
Share and warrant price				$ 9.1686
Gross proceeds from sale of stock				$ 38,000
Net proceeds from sale of stock				$ 35,200
Cantor Fitzgerald and Co. | At-the-market offering | Ordinary Shares
Stockholders' Equity
Number of shares issued					1,031,619
Gross proceeds from sale of stock					$ 37,800
Net proceeds from sale of stock					36,300
Value of shares unsold at termination date					12,200
Maximum aggregate gross proceeds under the sales agreement										$ 50,000
Jefferies LLC | At-the-market offering
Stockholders' Equity
Gross proceeds from sale of stock		$ 16,300				21,900
Net proceeds from sale of stock		$ 11,500				$ 20,400
Maximum aggregate gross proceeds under the sales agreement					$ 50,000				$ 50,000
Jefferies LLC | At-the-market offering | Ordinary Shares
Stockholders' Equity
Number of shares issued		3,933,350				1,992,390
Purchasers | Purchase agreement
Stockholders' Equity
Number of shares issued				4,144,537			1,379,310
Number of ordinary shares that can be purchased by warrant holders				4,144,537			1
Share and warrant price				$ 9.1686			$ 14.50
Warrants outstanding			4,059,532			4,059,532
Per share exercise price of right			$ 7.92			$ 7.92
Term			2 years			2 years
Gross proceeds from sale of stock							$ 20,000
Net proceeds from sale of stock							$ 18,300
Purchasers | Purchase agreement | Warrants Issued In December 2019
Stockholders' Equity
Warrants outstanding			1,379,310			1,379,310
Per share exercise price of right			$ 19			$ 19
Term			3 years			3 years
Purchasers | Purchase agreement | Warrants Issued In May 2020
Stockholders' Equity
Warrants outstanding			4,059,532			4,059,532
Per share exercise price of right			$ 7.92			$ 7.92
Term			2 years			2 years
Estimate | Jefferies LLC | At-the-market offering
Stockholders' Equity
Number of shares issued		3,933,350
Net proceeds from sale of stock		$ 11,500
Estimate | Jefferies LLC | At-the-market offering | Maximum
Stockholders' Equity
Gross proceeds from sale of stock		$ 16,300

Revenue (Details)

Revenue (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenue
Revenue accounted for under Topic 606			$ 5,027	$ 9,481	$ 9,656
Product revenue, gross			500
Sinovant Sciences, LTD | License Agreement
Revenue
Regulatory milestone payment received				500
Merck & Co | License Agreement
Revenue
Regulatory milestone payment received			1,800
Collaboration revenue
Revenue
Revenue accounted for under Topic 606			2,756	6,210	6,500
Collaboration revenue - Upfront payment
Revenue
Revenue accounted for under Topic 606			108	1,538
Product revenue, gross			484	2,173
Collaboration revenue - Upfront payment | License Agreement
Revenue
Revenue accounted for under Topic 606			1,000
Collaboration revenue - Upfront payment | Sinovant Sciences, LTD | License Agreement
Revenue
Revenue accounted for under Topic 606	$ 5,000	$ 1,000		1,000
Collaboration revenue - Upfront payment | Sunovion Pharmaceutics Canada, Inc.
Revenue
Revenue accounted for under Topic 606	$ 1,000
Collaboration revenue - Variable consideration | Sinovant Sciences, LTD | License Agreement
Revenue
Milestone payment received				5,000
Research premium
Revenue
Revenue accounted for under Topic 606			1,227	1,311	2,594
Government grants
Revenue
Revenue accounted for under Topic 606			$ 936	$ 422	$ 562

Revenue - Summary of Gross-To-N

Revenue - Summary of Gross-To-Net ("GTN") Adjustments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Product revenue, gross	$ 500
Adjustments To prior period accruals
Product revenue, net	5,027	$ 9,481	$ 9,656
Collaboration revenue - Upfront payment
Disaggregation of Revenue [Line Items]
Product revenue, gross	484	2,173
GTN accruals
Chargebacks and cash discounts	16	48
Medicaid and Medicare rebates	52	223
Other returns, rebates, discounts and adjustments	115	364
Total GTN accruals	(183)	(635)
Product revenue	301	1,538
Adjustments To prior period accruals
Returns reserve & GTN accrual adjustments	(421)
GTN accrual adjustments	228
Product revenue, net	$ 108	$ 1,538
XENLETA
Adjustments To prior period accruals
Percentage of inventory held	50.00%

Share-Based Payments - SOP 2015

Share-Based Payments - SOP 2015 (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Additional disclosures
Share-based compensation expense	$ 5,219	$ 9,748	$ 5,154
Stock Option Plan 2015
Options
Outstanding at beginning of year (in shares)	229,060	284,291	304,489
Forfeited (in shares)	(26,686)	(55,231)	(20,198)
Outstanding at end of year (in shares)	202,374	229,060	284,291
Vested and exercisable at end of year (in shares)	198,574	198,491	184,459
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)	$ 83.27	$ 83.41	$ 83.54
Forfeited (in dollars per share)	87.46	84.01	84.07
Outstanding balance at end of year (in dollars per share)	82.71	83.27	83.41
Vested and exercisable balance at end of year (in dollars per share)	$ 82.51	$ 81.98	$ 80.97
Fair Value Assumptions
Recognition period	2 months 12 days
Stock Option Plan 2015 | $4.06 per share to $11.00 per share
Additional disclosures
Exercise price minimum range	$ 40.60
Exercise price maximum range	$ 110
Weighted average remaining contractual life	5 years 4 months 24 days
Stock Option Plan 2015 | Stock Options
Share-Based Payments
Vesting period	4 years
Additional disclosures
Share-based compensation expense	$ 1,100	$ 4,000	$ 3,200
Fair Value Assumptions
Total unrecognized compensation related to unvested options	$ 200
Stock Option Plan 2015 | Stock Options | Maximum
Share-Based Payments
Exercise period	10 years
Stock Option Plan 2015 | Stock Options | Vesting period, year one
Share-Based Payments
Percentage that vests during the period	25.00%
Stock Option Plan 2015 | Stock Options | Vesting period, years 2-4
Share-Based Payments
Percentage that vests during the period	75.00%
Monthly vesting percentage	2.083%

Share-Based Payments - SOP 20_2

Share-Based Payments - SOP 2015 (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Additional disclosures
Share-based compensation expense	$ 5,219	$ 9,748	$ 5,154
Weighted-average remaining contractual life	8 years 8 months 12 days
Stock Option Plan 2015
Options
Outstanding at beginning of year (in shares)	229,060	284,291	304,489
Forfeited (in shares)	(26,686)	(55,231)	(20,198)
Outstanding at end of year (in shares)	202,374	229,060	284,291
Vested and exercisable at end of year (in shares)	198,574	198,491	184,459
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)	$ 83.27	$ 83.41	$ 83.54
Forfeited (in dollars per share)	87.46	84.01	84.07
Outstanding balance at end of year (in dollars per share)	82.71	83.27	83.41
Vested and exercisable balance at end of year (in dollars per share)	$ 82.51	$ 81.98	$ 80.97
Additional disclosures
Recognition period	2 months 12 days
Stock Option Plan 2015 | Stock Options
Share-Based Payments
Vesting period	4 years
Additional disclosures
Share-based compensation expense	$ 1,100	$ 4,000	$ 3,200
Total unrecognized compensation related to unvested options	$ 200
Stock Option Plan 2015 | Stock Options | Vesting period, year one
Share-Based Payments
Percentage that vests during the period	25.00%

Share-Based Payments - 2017 Sha

Share-Based Payments - 2017 Share Incentive Plan (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)tranche$ / sharesshares
Additional disclosures
Share-based compensation expense | $	$ 5,219	$ 9,748	$ 5,154
2017 Share Incentive Plan
Options
Outstanding at beginning of year (in shares) | shares	442,266	239,842	29,410
Granted (in shares) | shares	129,050	246,330	219,922
Forfeited (in shares) | shares	(128,472)	(43,906)	(9,490)
Outstanding at end of year (in shares) | shares	442,844	442,266	239,842
Vested and exercisable at end of year (in shares) | shares	228,731	112,028	11,928
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)	$ 35.48	$ 54.14	$ 69.17
Granted (in dollars per share)	13.50	19.51	52.71
Forfeited (in dollars per share)	29.39	47.87	67.52
Outstanding balance at end of year (in dollars per share)	30.89	35.48	54.14
Vested and exercisable balance at end of year (in dollars per share)	$ 39.02	$ 55.33	$ 68.77
Additional disclosures
Weighted average remaining contractual life	8 years 2 months 12 days
2017 Share Incentive Plan | $1.46 per share to $8.35 per share
Additional disclosures
Exercise price minimum range	$ 13.50
Exercise price maximum range	$ 81.90
2017 Share Incentive Plan | Stock Options
Fair Value Assumptions
Expected term of options (in years)	6 years 1 month 6 days	6 years	6 years 1 month 6 days
Dividend yield (as a percent)	0.00%	0.00%	0.00%
Additional disclosures
Share-based compensation expense | $	$ 2,000	$ 2,600	$ 1,800
Weighted-average grant date fair value (in dollars per share)	$ 7.97	$ 11.38	$ 30.64
Total unrecognized compensation related to unvested options | $	$ 2,600
Recognition period	10 months 24 days
2017 Share Incentive Plan | Stock Options | Minimum
Fair Value Assumptions
Expected volatility (as a percent)	63.80%	61.40%	59.80%
Risk-free interest rate (as a percent)	0.80%	1.90%	2.60%
2017 Share Incentive Plan | Stock Options | Maximum
Fair Value Assumptions
Expected volatility (as a percent)	64.00%	63.10%	61.40%
Risk-free interest rate (as a percent)	1.50%	2.60%	3.00%
2017 Share Incentive Plan | Restricted Stock Units ("RSUs")
Additional disclosures
Share-based compensation expense | $	$ 1,400	$ 2,700	$ 200
Recognition period	1 year 1 month 6 days
Restricted Stock Units
Number of shares outstanding | shares	151,269	90,169	122,210
weighted average fair value per share
Weighted average fair value at the beginning	$ 27.37	$ 33.10
Granted	13.50	19
Forfeited	17.23	27.87
Weighted average fair value at the end	$ 14.56	$ 27.37	$ 33.10
Additional Disclosures
Percentage that vests during the period	25.00%
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | XENLETA
Additional Disclosures
Number of vesting periods | tranche			3
Vesting period			6 months
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Immediate vesting upon regulatory approval | XENLETA
Additional Disclosures
Percentage that vests during the period			50.00%
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Immediate vesting upon regulatory approval | CONTEPO
Additional Disclosures
Percentage that vests during the period			50.00%
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting upon the one-year-anniversary of FDA approval | XENLETA
Additional Disclosures
Percentage that vests during the period			50.00%
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting upon the one-year-anniversary of FDA approval | CONTEPO
Additional Disclosures
Percentage that vests during the period			50.00%

Share-Based Payments - 2017 S_2

Share-Based Payments - 2017 Share Incentive Plan (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)tranche$ / sharesshares
Fair Value Assumptions
Weighted-average remaining contractual life	8 years 8 months 12 days
Stock-Based Compensation Expense
Share-based compensation expense | $	$ 5,219	$ 9,748	$ 5,154
2017 Share Incentive Plan
Options
Outstanding at beginning of year (in shares) | shares	442,266	239,842	29,410
Granted (in shares) | shares	129,050	246,330	219,922
Forfeited (in shares) | shares	(128,472)	(43,906)	(9,490)
Outstanding at end of year (in shares) | shares	442,844	442,266	239,842
Vested and exercisable at end of year (in shares) | shares	228,731	112,028	11,928
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)	$ 35.48	$ 54.14	$ 69.17
Granted (in dollars per share)	13.50	19.51	52.71
Forfeited (in dollars per share)	29.39	47.87	67.52
Outstanding balance at end of year (in dollars per share)	30.89	35.48	54.14
Vested and exercisable balance at end of year (in dollars per share)	$ 39.02	$ 55.33	$ 68.77
2017 Share Incentive Plan | Stock Options
Fair Value Assumptions
Expected term of options (in years)	6 years 1 month 6 days	6 years	6 years 1 month 6 days
Dividend yield (as a percent)	0.00%	0.00%	0.00%
Stock-Based Compensation Expense
Share-based compensation expense | $	$ 2,000	$ 2,600	$ 1,800
Weighted-average grant date fair value (in dollars per share)	$ 7.97	$ 11.38	$ 30.64
Unrecognized compensation expense
Total unrecognized compensation related to unvested options | $	$ 2,600
Recognition period	10 months 24 days
2017 Share Incentive Plan | Stock Options | Minimum
Fair Value Assumptions
Expected volatility (as a percent)	63.80%	61.40%	59.80%
Risk-free interest rate (as a percent)	0.80%	1.90%	2.60%
2017 Share Incentive Plan | Stock Options | Maximum
Fair Value Assumptions
Expected volatility (as a percent)	64.00%	63.10%	61.40%
Risk-free interest rate (as a percent)	1.50%	2.60%	3.00%
2017 Share Incentive Plan | Restricted Stock Units ("RSUs")
Share-Based Payments
Fair Value | $	$ 1,700	$ 2,100
Stock-Based Compensation Expense
Share-based compensation expense | $	1,400	$ 2,700	$ 200
Unrecognized compensation expense
Unrecognized compensation costs | $	$ 1,300
Recognition period	1 year 1 month 6 days
Restricted Stock Units
Percentage that vests during the period	25.00%
Weighted average grant date fair value per share	$ 13.50	$ 19
Number of shares outstanding | shares	90,169	122,210
Granted | shares	155,730	47,900
Vested and issued | shares	51,671	(65,758)
Forfeited | shares	(42,959)	(14,183)
Number of shares outstanding | shares	151,269	90,169	122,210
weighted average fair value per share
Weighted average fair value at the beginning	$ 27.37	$ 33.10
Granted	13.50	19
Vested and issued	30.95	31.80
Forfeited	17.23	27.87
Weighted average fair value at the end	$ 14.56	$ 27.37	$ 33.10
XENLETA | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs")
Share-Based Payments
Number of vesting periods | tranche			3
Vesting period			6 months
XENLETA | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Immediate vesting upon regulatory approval
Restricted Stock Units
Percentage that vests during the period			50.00%
XENLETA | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting upon the one-year-anniversary of FDA approval
Restricted Stock Units
Percentage that vests during the period			50.00%
CONTEPO | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Immediate vesting upon regulatory approval
Restricted Stock Units
Percentage that vests during the period			50.00%
CONTEPO | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting upon the one-year-anniversary of FDA approval
Restricted Stock Units
Percentage that vests during the period			50.00%

Share-Based Payments - 2019 Ind

Share-Based Payments - 2019 Inducement Share Incentive Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Mar. 12, 2019
Weighted average exercise price in $ per share
Share-based compensation expense	$ 5,219,000	$ 9,748,000	$ 5,154,000
Fair Value Assumptions
Weighted-average remaining contractual life	8 years 8 months 12 days
2019 Inducement Plan
Options
Outstanding at beginning of year (in shares)	60,565
Granted (in shares)	18,200	70,315
Forfeited (in shares)	(52,950)	(9,750)
Outstanding at end of year (in shares)	25,815	60,565
Vested and exercisable at end of year (in shares)	4,396
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)	$ 21.45
Granted (in dollars per share)	13.50	$ 22.20
Forfeited (in dollars per share)	19.59	26.92
Outstanding balance at end of year (in dollars per share)	19.04	$ 21.45
Vested and exercisable balance at end of year (in dollars per share)	$ 26.96
Share-based compensation expense	$ 38,000,000	$ 77,000
Weighted-average grant date fair value (in dollars per share)	$ 7.93
Unrecognized compensation expense
Exercise price minimum range	13.50
Exercise price maximum range	$ 29.90
2019 Inducement Plan | Ordinary Shares
Share-Based Payments
Shares reserved for future issuance				200,000
2019 Inducement Plan | Stock Options
Weighted average exercise price in $ per share
Weighted-average grant date fair value (in dollars per share)		$ 13.04
Fair Value Assumptions
Expected term of options (in years)	6 years 1 month 6 days	6 years 1 month 6 days
Unrecognized compensation expense
Total unrecognized compensation related to unvested options	$ 200,000
Recognition period	1 year 2 months 12 days
2019 Inducement Plan | Stock Options | Minimum
Fair Value Assumptions
Expected volatility (as a percent)	63.70%	59.80%
Risk-free interest rate (as a percent)	0.96%	2.55%
2019 Inducement Plan | Stock Options | Maximum
Fair Value Assumptions
Expected volatility (as a percent)	64.00%	61.40%
Risk-free interest rate (as a percent)	1.37%	3.03%

Share-Based Payments - Share-Ba

Share-Based Payments - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-Based Payments
Share-based compensation expense	$ 5,219	$ 9,748	$ 5,154
Research and development
Share-Based Payments
Share-based compensation expense	$ 1,280	$ 2,138	$ 1,406

Share-Based Payments - Induceme

Share-Based Payments - Inducement Awards Outside of the 2019 Inducement Plan (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-Based Payments
Share-based compensation expense		$ 5,219,000	$ 9,748,000	$ 5,154,000
Additional disclosures
Weighted-average remaining contractual life		8 years 8 months 12 days
Inducement Awards Outside of the 2019 Inducement Plan
Share-Based Payments
Share-based compensation expense		$ 400,000	$ 400,000
Fair Value Assumptions
Expected volatility (as a percent)		59.80%
Expected term of options (in years)		6 years 1 month 6 days
Risk-free interest rate (as a percent)		2.90%
Dividend yield (as a percent)		0.00%
Additional disclosures
Weighted-average remaining contractual life		7 years 7 months 6 days
Total unrecognized compensation related to unvested options		$ 700,000
Recognition period		9 months 18 days
Inducement Awards Outside of the 2019 Inducement Plan | Vesting period, year one
Share-Based Payments
Percentage that vests during the period	25.00%
Inducement Awards Outside of the 2019 Inducement Plan | Vesting period, years 2-4
Share-Based Payments
Percentage that vests during the period	75.00%
Monthly vesting period	36 months
Inducement Awards Outside of the 2019 Inducement Plan | Non-statutory option
Share-Based Payments
Vesting period	4 years
Options exercise price (in dollars per share)	$ 35.30
Exercise period	10 years
Options weighted average grant date fair value (in dollars per share)		$ 20.50
Inducement Awards Outside of the 2019 Inducement Plan | Non-statutory option | Chief Executive Officer
Share-Based Payments
Options granted during the period	85,000
Inducement Awards Outside of the 2019 Inducement Plan | Restricted Stock Units ("RSUs")
Share-Based Payments
Granted		$ 35.30
Inducement Awards Outside of the 2019 Inducement Plan | Restricted Stock Units ("RSUs") | Chief Executive Officer
Share-Based Payments
Restricted stock granted during the period	15
Inducement Awards Outside of the 2019 Inducement Plan | Restricted Stock Units ("RSUs") | Upon receipt of FDA approval
Share-Based Payments
Percentage that vests during the period	50.00%
Inducement Awards Outside of the 2019 Inducement Plan | Restricted Stock Units ("RSUs") | First anniversary of FDA approval
Share-Based Payments
Percentage that vests during the period	50.00%
2019 Inducement Plan
Share-Based Payments
Options granted during the period		18,200	70,315
Options exercise price (in dollars per share)		$ 19.04	$ 21.45
Options weighted average grant date fair value (in dollars per share)		$ 7.93
Share-based compensation expense		$ 38,000,000	$ 77,000

Share-Based Payments - 2020 Sha

Share-Based Payments - 2020 Share Incentive Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Mar. 04, 2020
Share-Based Payments
Share-based compensation expense	$ 5,219,000	$ 9,748,000	$ 5,154,000
Additional disclosures
Weighted-average remaining contractual life	8 years 8 months 12 days
Research and development
Share-Based Payments
Share-based compensation expense	$ 1,280,000	2,138,000	1,406,000
Selling, general and administrative
Share-Based Payments
Share-based compensation expense	$ 3,939,000	$ 7,610,000	$ 3,748,000
2020 Share Incentive Plan
Share-Based Payments
Options granted during the period	317,805
Exercise price (in dollars per share)	$ 10.24
Share-based compensation expense	$ 144,000,000
Grant date fair value	$ 4.40
Options
Granted (in shares)	317,805
Forfeited (in shares)	(21,000)
Outstanding at end of year (in shares)	296,805
Weighted average exercise price in $ per share
Granted (in dollars per share)	$ 10.24
Forfeited (in dollars per share)	7.88
Outstanding balance at end of year (in dollars per share)	$ 10.18
Ordinary Shares | 2020 Share Incentive Plan
Share-Based Payments
Shares reserved for future issuance	820,022
Ordinary Shares | Maximum | 2020 Share Incentive Plan
Share-Based Payments
Shares reserved for future issuance				930,000
Stock Options | 2020 Share Incentive Plan
Share-Based Payments
Options granted during the period	296,805
Options
Granted (in shares)	296,805
Additional disclosures
Weighted-average remaining contractual life	9 years 7 months 6 days
Total unrecognized compensation related to unvested options	$ 1,300,000
Recognition period	1 year 7 months 6 days
Stock Options | Minimum | 2020 Share Incentive Plan
Share-Based Payments
Exercise price (in dollars per share)	$ 2.42
Weighted average exercise price in $ per share
Granted (in dollars per share)	$ 2.42
Fair Value Assumptions
Expected volatility (as a percent)	73.00%
Expected term of options (in years)	5 years 6 months
Risk-free interest rate (as a percent)	0.34%
Stock Options | Maximum | 2020 Share Incentive Plan
Share-Based Payments
Exercise price (in dollars per share)	$ 13.50
Weighted average exercise price in $ per share
Granted (in dollars per share)	$ 13.50
Fair Value Assumptions
Expected volatility (as a percent)	74.40%
Expected term of options (in years)	6 years 1 month 6 days
Risk-free interest rate (as a percent)	0.51%
Restricted Stock Units ("RSUs") | 2020 Share Incentive Plan | Employees
Share-Based Payments
Options granted during the period	45,977
Number of vesting periods	3
Vesting period	6 months
Grant date fair value	$ 7.88
Options
Granted (in shares)	45,977
Performance Based Restricted Stock Unit | 2020 Share Incentive Plan | Employees
Share-Based Payments
Options granted during the period	43,125
Share-based compensation expense	$ 111,000,000,000
Grant date fair value	$ 5.30
Options
Granted (in shares)	43,125
Additional disclosures
Total unrecognized compensation related to unvested RSUs	$ 500,000
Recognition period	1 year

Share-Based Payments - Employee

Share-Based Payments - Employee Stock Purchase Plan (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Aug. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-Based Payments
Share-based compensation expense		$ 5,219	$ 9,748	$ 5,154
Employee Stock Purchase Plan
Share-Based Payments
Maximum number of shares authorized under plan (in shares)	50,000
ESPP Share Pool as a percentage of total number of ordinary shares outstanding		0.10%
Purchase discount as a percentage of current market price		15.00%

Post-employment benefit oblig_2

Post-employment benefit obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Austria
Post-employment benefit obligations
Employer monthly contribution (as a percent)	1.53%	1.53%	1.53%
Contribution costs	$ 57,000	$ 68,000	$ 68,000
U.S.
Post-employment benefit obligations
Contribution costs	$ 396,000	$ 710,000	$ 448,000
Percent of match, first level	100.00%	100.00%	100.00%
Employee voluntary contribution, first level	3.00%	3.00%	3.00%
Percent match, second level	50.00%	50.00%	50.00%
Employee voluntary contribution, second level	2.00%	2.00%	2.00%

Income tax expense - Components

Income tax expense - Components (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Loss before income taxes attributable to domestic and international operations
Domestic	$ (71,344)	$ (78,761)	$ (113,699)
Foreign	1,999	(3,902)	(1,032)
Loss before income taxes	(69,345)	(82,663)	(114,731)
Current tax
Foreign	(139)	(101)	(49)
Total income tax expense	$ (139)	$ (101)	$ (49)
Effective income tax reconciliation
Statutory income tax rate	12.50%	12.50%	12.50%
Non-deductible expenses		(0.10%)	(0.10%)
Income not subject to tax	0.20%	0.30%	0.30%
Tax credits	0.60%	0.40%	0.10%
Foreign rate differential	3.00%	0.60%	(3.10%)
In-process research and development			(3.50%)
Tax audit assessments		(11.80%)
Other	2.30%	0.80%	0.20%
Valuation allowance	(18.80%)	(2.80%)	(6.50%)
Effective income tax rate	(0.20%)	(0.10%)	(0.10%)
Ireland
Effective income tax reconciliation
Statutory income tax rate	12.50%	12.50%	12.50%

Income tax expense - Deferred I

Income tax expense - Deferred Income Tax (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforwards	$ 108,095	$ 94,014
Tax loss on liquidation of subsidiary	4,029	5,024
Equity compensation	4,449	4,182
Non-deductible reserves	447	395
Total deferred tax assets	117,020	103,615
Valuation allowance	(116,200)	(103,185)	$ (100,832)	$ (80,087)
Net deferred tax assets	820	430
Deferred tax liabilities:
Financial liabilities	757	48
Property, plant and equipment	63	382
Total deferred tax liability	820	430
Deferred tax, net	$ 0	$ 0

Income tax expense - Valuation

Income tax expense - Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income tax (expense) benefit
Balance at beginning of year	$ (103,185)	$ (100,832)	$ (80,087)
Balance at end of year	(116,200)	(103,185)	(100,832)
Tax benefit
Income tax (expense) benefit
Change in valuation allowance	$ (13,015)	$ (2,353)	(7,301)
Acquired tax attributes
Income tax (expense) benefit
Change in valuation allowance			$ (13,444)

Income tax expense - Net Operat

Income tax expense - Net Operating Losses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net operating losses carryforwards
Period in which the company is in cumulative loss position.	3 years
Valuation allowance	$ 116,200	$ 103,185	$ 100,832	$ 80,087
Uncertain tax positions disclosures
Uncertain tax positions	0
Ireland
Net operating losses carryforwards
Net operating losses carryforwards	251,775
Austria
Net operating losses carryforwards
Net operating losses carryforwards	248,563
U.S.
Net operating losses carryforwards
Net operating losses carryforwards	10,401
Net operating losses carryforwards	$ 35,516

Earnings (Loss) per Share - Bas

Earnings (Loss) per Share - Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Basic and diluted loss per share
Net loss for the period	$ (69,484)	$ (82,764)	$ (114,780)
Weighted average number of shares outstanding	12,845,089	7,419,948	5,079,576
Basic and diluted loss per share	$ (5.41)	$ (11.15)	$ (22.60)

Earnings (Loss) per Share - Ant

Earnings (Loss) per Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Stock Options
Anti-dilutive stock options
Ordinary share equivalents excluded from the calculations of diluted earnings per share	1,052,838	816,891	609,134
Restricted Stock Units ("RSUs")
Anti-dilutive stock options
Ordinary share equivalents excluded from the calculations of diluted earnings per share	239,384	105,169	137,210
Warrants
Anti-dilutive stock options
Ordinary share equivalents excluded from the calculations of diluted earnings per share	5,438,842	1,379,310

Acquisition of Zavante (Details

Acquisition of Zavante (Details) - Zavante Therapeutics $ in Millions	Jul. 24, 2018USD ($)shares
Acquisition of Zavante
Percentage of entity shares held by subsidiary	19.90%
Milestone payment receivable prior acquisition	$ 3
Threshold milestone payment that may be settled in ordinary shares	26
In-process research and development expense	32
Transaction costs	4.8
Net liabilities assumed	0.2
Maximum
Acquisition of Zavante
Contingent consideration	$ 97.5
Upfront Shares
Acquisition of Zavante
Business acquisition, shares issued or issuable | shares	733,690
Expense from the fair value of shares issued in the acquisition	$ 26.9
Holdback Shares
Acquisition of Zavante
Business acquisition, shares issued or issuable | shares	81
Approval Milestone Payment
Acquisition of Zavante
Contingent consideration	$ 25
Net Sales Milestone Payments
Acquisition of Zavante
Contingent consideration	$ 72.5

Significant Arrangements and _2

Significant Arrangements and License Agreements (Details) $ in Thousands	Jul. 10, 2020USD ($)	Nov. 30, 2020employee	Sep. 30, 2020employee	Mar. 31, 2018USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
License Agreement
Revenue accounted for under Topic 606								$ 5,027	$ 9,481	$ 9,656
Number Of Sales Representatives | employee		60	15
Collaboration revenue - Upfront payment
License Agreement
Revenue accounted for under Topic 606								108	1,538
Sunovion Pharmaceutics Canada, Inc. | NDS Approval
License Agreement
Revenue accounted for under Topic 606	$ 500
Sunovion Pharmaceutics Canada, Inc. | Collaboration revenue - Upfront payment
License Agreement
Revenue accounted for under Topic 606				$ 1,000
License Agreement | Collaboration revenue - Upfront payment
License Agreement
Revenue accounted for under Topic 606								$ 1,000
License Agreement | Sinovant Sciences, LTD
License Agreement
Notice period for termination of agreement								180 days
License Agreement | Sinovant Sciences, LTD | Achievement of certain regulatory and commercial milestones
License Agreement
Maximum contingent milestone payment					$ 91,500			$ 91,500
License Agreement | Sinovant Sciences, LTD | Subsequent regulatory approval
License Agreement
Maximum contingent milestone payment					4,000			4,000
License Agreement | Sinovant Sciences, LTD | Clinical trial application submission
License Agreement
Proceeds from license agreement, milestone							$ 1,500
License Agreement | Sinovant Sciences, LTD | FDA approval
License Agreement
Revenue accounted for under Topic 606						$ 5,000
License Agreement | Sinovant Sciences, LTD | Approval of XENLETA
License Agreement
Revenue accounted for under Topic 606					5,000
License Agreement | Sinovant Sciences, LTD | Additional regulatory approvals and annual sales targets
License Agreement
Remaining milestone payments					86,500			$ 86,500
License Agreement | Sinovant Sciences, LTD | Collaboration revenue - Upfront payment
License Agreement
Revenue accounted for under Topic 606				$ 5,000	$ 1,000				1,000
License Agreement | Sinovant Sciences, LTD | Collaboration revenue - Variable consideration
License Agreement
Proceeds from license agreement, milestone									$ 5,000

Commitments and Contingencies -

Commitments and Contingencies - Operating Leases (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Feb. 28, 2021ft²	Oct. 31, 2020ft²	Dec. 31, 2020USD ($)	Dec. 31, 2020EUR (€)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Leases
Operating lease liabilities | $			$ 168
Operating Lease, Liability, Statement of Financial Position [Extensible List]			Other Liabilities, Noncurrent
Operating lease expense | $			$ 1,400		$ 1,500	$ 1,400
King of Prussia
Leases
Operating lease terminated area | ft²		15,000
Weighted-average remaining lease term of operating leases			3 months 18 days
Weighted-average discount rate (as a percent)			9.80%
Fort Washington, Pennsylvania
Leases
Operating lease, sublease area | ft²	8,000
Lease Agreement | Vienna, Austria
Leases
Operating lease, existence of option to terminate			true	true
Termination notice period			6 months	6 months
Lease Agreement | Dublin, Ireland
Leases
Operating lease, existence of option to renew			true	true
Operating lease, monthly based fixed amount | €				€ 7,000
Lease Agreement | Dublin, Ireland | Minimum
Leases
Operating lease, renewal term			3 months

Commitments and Contingencies_2

Commitments and Contingencies - Additional Lease Disclosures and Other Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Cash Flows Supplemental Information:
Cash paid for amounts included in the measurement of the operating lease liabilities	$ 507	$ 515
Right-of-use assets obtained in exchange for operating lease obligations	226	$ 1,647
Future payments of operating lease liabilities, ASC 842
2021	171
Total lease payments	171
Less imputed interest and amortization differences	(3)
Present value of operating lease liabilities	168
Future minimum expected lease payments under non-cancelable operating leases, ASC 840
Total	743
2021	743
Other contractual commitments
Total	58,166
2021	14,059
2022	12,569
2023	12,838
2024	9,350
2025	9,350
Future minimum contractual obligations and commitments
Total	58,909
2021	14,802
2022	12,569
2023	12,838
2024	9,350
2025	9,350
Other Commitments and Contingencies
Contingent liabilities	$ 0

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 01, 2021	Mar. 31, 2021	May 31, 2020	Dec. 31, 2019	Dec. 31, 2020
Subsequent Event [Line Items]
Ordinary stock, nominal value (in dollars per share)				$ 0.01	$ 0.01
Proceeds from sale of stock, net of commissions			$ 35.2
Purchase agreement
Subsequent Event [Line Items]
Number of shares issued			4,144,537
Number of ordinary shares that can be purchased by warrant holders			4,144,537
Proceeds from sale of stock, net of commissions			$ 35.2
Purchasers | Purchase agreement
Subsequent Event [Line Items]
Number of shares issued			4,144,537	1,379,310
Number of ordinary shares that can be purchased by warrant holders			4,144,537	1
Proceeds from sale of stock, net of commissions				$ 18.3
Exercise price					$ 7.92
Term					2 years
Purchasers | Purchase agreement | Subsequent Event
Subsequent Event [Line Items]
Number of shares issued	9,761,010	9,761,010
Number of ordinary shares that can be purchased by warrant holders	4,880,505	4,880,505
Proceeds from sale of stock, net of commissions		$ 23.4
Gross proceeds from public offering		$ 25.4
Term		5 years
Ordinary Share Warrants | Purchasers | Purchase agreement | Subsequent Event
Subsequent Event [Line Items]
Ordinary stock, nominal value (in dollars per share)	$ 0.01	$ 0.01
Number of ordinary shares that can be purchased by warrant holders		300,000
Share and warrant price		$ 2.4525
Exercise price		$ 2.39
Pre-Funded Warrants | Purchasers | Purchase agreement | Subsequent Event
Subsequent Event [Line Items]
Number of ordinary shares that can be purchased by warrant holders		600,000
Share and warrant price		$ 2.4425
Exercise price		$ 0.01